


PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 495/04, A61K 31/435 // (C07D 495/04, 333:00, 221:00)	A1	(11) International Publication Number: WO 97/14697 (43) International Publication Date: 24 April 1997 (24.04.97)
(21) International Application Number: PCT/JP96/03018 (22) International Filing Date: 18 October 1996 (18.10.96) (30) Priority Data: 7/271639 19 October 1995 (19.10.95) JP (71) Applicant (for all designated States except US): TAKEDA CHEMICAL INDUSTRIES, LTD. [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541 (JP). (72) Inventors; and (75) Inventors/Applicants (for US only): FURUYA, Shuichi [JP/JP]; 7-9-603, Kasuga 1-chome, Tsukuba-shi, Ibaraki 305 (JP). CHOH, Nobuo [JP/JP]; 7-9-502, Kasuga 1-chome, Tsukuba-shi, Ibaraki 305 (JP). HARADA, Masataka [JP/JP]; 12-1-404, Matsushiro 3-chome, Tsukuba-shi, Ibaraki 305 (JP). SASAKI, Satoshi [JP/JP]; 254-7, Oaza-Ohsuna, Tsukuba-shi, Ibaraki 300-33 (JP). (74) Agents: ASAHINA, Tadao et al.; Osaka Plant of Takeda Chemical Industries, Ltd., 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532 (JP).	(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

(54) Title: THIENOPYRIDINE DERIVATIVES AS GONADOTROPIN RELEASING HORMONE ANTAGONISTS**(57) Abstract**

The present thienopyrimidine derivatives of formula (I) and compositions having gonadotropin-releasing hormone antagonistic activity are useful as prophyactics or therapeutic agents for the prevention or treatment of several hormone dependent diseases, for example, a sex hormone dependent cancer (e.g., prostatic cancer, uterine cervical cancer, breast cancer, pituitary adenoma), benign prostatic hypertrophy, myoma of the uterus, endometriosis, precocious puberty, amenorrhea, premenstrual syndrome, polycystic ovary syndrome and acne vulgaris; are effective as a fertility controlling agent in both sexes (e.g., a pregnancy controlling agent and a menstrual cycle controlling agent); can be used as a male or female contraceptive, as an ovulation-inducing agent; can be used as an infertility treating agent by using a rebound effect owing to a stoppage of administration thereof; and are useful for modulating estrous cycles in animals in the field of animal husbandry, as agents for improving the quality of edible meat or promoting the growth of animals; and as agents for promoting spawning in fish.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

DESCRIPTION

THIENOPYRIDINE DERIVATIVES AS GONADOTROPIN RELEASING HORMONE ANTAGONISTS

5

Technical Field

The present invention relates to novel thieno[2,3-b]pyridine derivatives and salts thereof. The present invention further relates to methods for manufacturing these thieno[2,3-b]pyridine derivatives and the salts thereof, and pharmaceutical compositions containing these thieno[2-3,b]pyridine derivatives.

Background Art

15 Secretion of anterior pituitary hormone is controlled by peripheral hormones secreted from target organs for the respective hormones and by secretion-accelerating or -inhibiting hormones from the hypothalamus, which is the upper central organ of the anterior lobe of the pituitary (in this specification, these hormones are collectively called "hypothalamic hormones"). At the present stage, as hypothalamic hormones, nine kinds of hormones have been confirmed including, for example, thyrotropin releasing hormone (TRH) or gonadotropin releasing hormone {GnRH: sometimes called LH-RH (luteinizing hormone releasing hormone)} (cf. Seirigaku 2, compiled by M. Iriku and K Toyama, published by Bunkohdo, pp.610-618, 1986). These hypothalamic hormones are assumed to show their actions via the receptor which is considered to exist in the anterior lobe of the pituitary (cf. ibid), and studies of receptor genes specific to these hormones, including those of humans, have been developed (Receptor Kiso To Rinshô, compiled by H. Imura, et al., published by Asakura Shoten, pp.297-304, 1993). Accordingly, antagonists or agonists specifically and

selectively acting on these receptors control the action of hypothalamic hormone and the secretion of anterior pituitary hormone. As a result, they are expected to be useful as prophylactic and therapeutic agents of anterior pituitary hormone dependent diseases.

As compounds having a GnRH antagonistic activity, a number of compounds including, for example, derivatives of GnRH such as straight-chain peptides, (US Patent No. 5140009 and No. 5171835), cyclic hexapeptide derivatives [Japanese Patent Application Laid-open No. 61(1986)-191698] or bicyclic peptide derivatives [Journal of medicinal chemistry, Vol.36, pp.3265-3273, 1993] have been disclosed.

These compounds are, however, all peptides, which leave many problems including, for example, dosage forms, stability of drugs, durability of actions and stability on metabolism. Orally administrable GnRH antagonistic drugs, especially non-peptide ones, which has therapeutic effects for hormone-dependent cancer, e.g. prostate cancer, and for endometriosis and precocious puberty, but not to cause the transient pituitary-gonadotropic action (acute action) have been desired, are strongly desired.


The object of the invention lies in providing novel thieno[2,3-b]pyridine compounds having excellent gonadotropic hormone releasing hormone antagonistic activity as well as being excellent gonadotropic hormone releasing hormone antagonistic agents.

Disclosure of Invention


Thus, the present invention provides

(1) A compound of the formula:

3



wherein each of R^1 and R^2 are hydrogen or a group bonded through a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom, R^3 is an optionally substituted homo-or hetero-cyclic group, R^4 is an optionally substituted heterocyclic group or a group bonded through a hetero atom, R^5 is hydrogen or a group bonded through a carbon atom, n is an integer of 0 to 3, with the proviso that when R^4 is tetrazolyl or a group bonded through a hetero atom and n is 1, R^3 is not a group of the formula:



wherein R^7 is an optionally substituted 5-7 membered heterocyclic residue, having as a group capable of constituting the ring, carbonyl group, thiocarbonyl group, an optionally oxidized sulfur atom or a group convertible into them, D is a direct bond or a spacer having an atomic length of two or less between the ring B and the ring A, and A and B are independently an optionally substituted aromatic hydrocarbon residue optionally containing a hetero-atom or an optionally substituted heterocyclic residue, or a salt thereof,

(2) A compound according to the item (1), wherein R^1 is a group bonded through a carbon atom or a nitrogen atom,

- (3) A compound according to the item (1), wherein R^1 is an optionally substituted C_{1-20} hydrocarbon residue,
- (4) A compound according to the item (1), wherein R^1 is an optionally substituted C_{1-6} alkyl group,
- (5) A compound according to the item (3), wherein C_{1-20} hydrocarbon residue of R^1 is optionally substituted with (1) halogen, (2) nitro, (3) cyano, (4) an optionally substituted amino, (5) an optionally substituted hydroxyl group, (6) a group of the formula: $-S(O)_t-R^6$, wherein t denotes an integer of 0 to 2, and R^6 is a hydrogen atom or an optionally substituted hydrocarbon residue,
- (6) A compound according to the item (1), wherein R^2 is an optionally substituted C_{1-20} hydrocarbon residue,
- (7) A compound according to the item (1), wherein R^2 is an optionally substituted C_{6-14} aryl group,
- (8) A compound according to the item (6), wherein C_{1-20} hydrocarbon residue of R^2 is optionally substituted with (1) an optionally substituted amino group, (2) an optionally substituted hydroxyl group, (3) an optionally substituted carbamoyl group, (4) an optionally substituted carboxyl group, (5) an optionally substituted alkenyl group, (6) acyl or (7) nitro,
- (9) A compound according to the item (1), wherein R^1 is an optionally substituted homo-cyclic group,
- (10) A compound according to the item (9), wherein R^1 is an optionally substituted C_{6-14} aryl group,

(11) A compound according to the item (9), wherein
homo-cyclic group of R^3 is optionally substituted with
(1) halogen, (2) nitro, (3) an optionally substituted
hydroxyl group, (4) a group of the formula: $-S(O)_t-R^6$,
5 wherein t denotes an integer of 0 to 2, and R^6 is a
hydrogen atom or an optionally substituted hydrocarbon
residue,

(12) A compound according to the item (1), wherein
10 heterocyclic group of R^4 is 5- to 8-membered
heterocyclic group,

(13) A compound according to the item (1), wherein
heterocyclic group of R^4 is 5- to 8-membered
15 heterocyclic group having at least one nitrogen atom in
a ring,

(14) A compound according to the item (1), wherein the
group bonded through hetero atom of R^4 is an optionally
20 substituted amino group, an optionally substituted
hydroxyl group or an optionally substituted mercapto
group,

(15) A compound according to the item (1), wherein the
25 substituent in the optionally substituted heterocyclic
group of R^4 is (1) halogen, (2) nitro, (3) an
optionally substituted hydroxyl group, (4) a group of
the formula: $-S(O)_t-R^6$, wherein t denotes an integer of
0 to 2, and R^6 is a hydrogen atom or an optionally
30 substituted hydrocarbon residue, (5) an optionally
substituted amino, or (6) a C_{1-10} hydrocarbon residue,

(16) A compound according to the item (14), wherein the
optionally substituted amino group, the optionally
35 substituted hydroxyl group or the optionally

substituted mercapto group is (1) a C₁₋₁₀ hydrocarbon residue which may optionally be substituted by C₁₋₆ alkoxy-carbonyl or carbamoyl, (2) a C₁₋₁₀ acyl group, or (3) a group of the formula: -S(O)_t-R⁶, wherein t denotes an integer of 0 to 2, and R⁶ is a hydrogen atom or an optionally substituted hydrocarbon residue,

(17) A compound according to the item (1), wherein R⁵ is a hydrogen atom or an optionally substituted C₁₋₂₀ hydrocarbon residue,

(18) A compound according to the item (17), wherein hydrocarbon residue in the optionally substituted C₁₋₂₀ hydrocarbon residue is C₁₋₁₀ alkyl group,


(19) A compound according to the item (1), wherein R¹ is an alkyl group which may optionally be substituted with halogen or N-C₇₋₁₃ aralkyl-N-C₁₋₆ alkylamino, R² is a C₆₋₁₄ aryl group which may optionally be substituted with a group selected from the group consisting of (i) nitro, (ii) C₁₋₆ alkoxy and (iii) amino which may optionally be substituted with C₁₋₆ alkanoyl, R³ is a mono- or di-halogeno-C₆₋₁₄ aryl group, R⁴ is (1) a 5- or 6- membered heterocyclic group which has at least one nitrogen atom and one oxygen atom and which is bonded through a carbon atom, (2) a hydroxyl group which may optionally be substituted with a group selected from the group consisting of (i) C₁₋₆ alkyl which may optionally be substituted with C₁₋₆ alkoxy-carbonyl or carbamoyl, (ii) C₁₋₆ alkanoyl and (iii) C₁₋₆ alkylsulfonyl, (3) a group of the formula: -S(O)_t-R^{6'}, wherein t is an integer of 0 to 2 and R^{6'} is C₁₋₆ alkyl, or (4) an amino group which may optionally be substituted with C₁₋₆ alkanoyl, R⁵ is a hydrogen atom and n is 1,

(20) 3-(N-benzyl-N-methylaminomethyl)-4,7-dihydro-2-(4-methoxyphenyl)-5-(oxazol-5-yl)-7-(2-fluorobenzyl)-4-oxothieno[2,3-b]pyridine or its salt,


5 (21) 4,7-dihydro-2-(4-isobutyrylamino-phenyl)-(3-(N-benzyl-N-methylaminomethyl)-5-isopropoxy-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine or its salt,

10 (22) 4,7-dihydro-2-(4-isobutyrylamino-phenyl)-3-(N-benzyl-N-methylaminomethyl)-5-isopropylsulfonyloxy-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine or its salt,

15 (23) A method for producing a compound of the formula:



20 wherein $R^{1'}$ is a group bonded through a nitrogen atom, R^2 , R^3 , R^4 and R^5 have the same meaning as defined in the item (1), n is an integer of 0 to 3, m is an integer of 0 to 6, or a salt thereof, which comprises
25 reacting a compound of the formula:



30 wherein X is a leaving group and the other group have the same meaning as defined above, with a compound of the formula:

35 $R^{1'}-H$

wherein $R^{1'}$ has the same meaning as defined above,

(24) A pharmaceutical composition, which comprises a compound as defined in the item (1) and a carrier, excipient or diluent thereof,

5 (25) A pharmaceutical composition according to the item (24), which is for antagonizing gonadotropin-releasing hormone activity,


10 (26) A pharmaceutical composition according to the item (25), which is a composition for treating or preventing a sex hormone dependent disease,

15 (27) A method for treating a mammal suffering from a gonadotropin-releasing hormone derived disorder, which comprises administering an effective amount of a compound as defined in the item 1 to the mammal, and

20 (28) Use of a compound as defined in the item (1) for producing a pharmaceutical composition for antagonizing gonadotropin-releasing hormone activity in a mammal suffering from a sex hormone dependent disease.

The nucleus of the present compound, 4,7-dihydro-4-oxo-thieno[2,3-b]pyridine, is shown below;

25



30

The group bonded through a carbon atom represented by R^1 , R^2 or R^5 in the formula (I), (II) or (III) includes, for example, (1) a hydrocarbon residue, (2) an acyl group, (3) a carbamoyl group, and (4) a heterocyclic group which bonds through carbon atom of the heterocyclic group. Each of these groups may

35

optionally be substituted. Furthermore, as the group bonded through a carbon atom, (5) a carboxyl group or an ester or amide thereof and (6) a cyano group are mentioned.

5 The ester of carboxyl group includes a group of the formula: $-\text{COO}-\text{R}^{11}$, wherein R^{11} is a hydrogen atom, a hydrocarbon residue or a heterocyclic group. Each of these hydrocarbon residue and heterocyclic group may optionally be substituted.

10 The amide of carboxyl group includes a group of the formula; $-\text{CO}-\text{NR}^{12}\text{R}^{13}$, wherein R^{12} is a hydrogen atom, a hydrocarbon residue or a heterocyclic group or a group bonded through a sulfur atom. R^{13} represents a hydrogen atom or a hydrocarbon residue. R^{12} and R^{13} may
15 form a 5 to 7 membered cyclic amino group together with the neighboring nitrogen atom or a nitrogen-containing heterocyclic group together with a neighboring nitrogen atom. Each of these hydrocarbon residue, heterocyclic group, cyclic amino group, nitrogen-containing
20 heterocyclic group may optionally be substituted.

 Examples of the group bonded through a nitrogen atom represented by R^1 and R^2 include (1) a nitro group, (2) a group of the formula: $-\text{NR}^{14}\text{R}^{15}$, wherein R^{14} represents a hydrogen atom, a hydrocarbon residue, a
25 hydrocarbon residue-oxy group, an acyl group, a hydroxyl group, a heterocyclic group, a group of the formula: $-\text{SO}_p-\text{R}^{16}$, wherein p denotes an integer of 1 or 2, and R^{16} represents a hydrocarbon residue, R^{15} represents a hydrogen or a hydrocarbon residue, and the
30 group $-\text{NR}^{14}\text{R}^{15}$ may form a cyclic amino group. Each of these hydrocarbon residue, hydrocarbon residue-oxy group, acyl group, hydroxyl group, heterocyclic group and cyclic amino group may optionally be substituted.

 Examples of the group bonded through an oxygen
35 atom of R^1 and R^2 include a group of the formula: $-\text{O}-$

R^{17} , wherein R^{17} is a hydrogen atom, a hydrocarbon residue, an acyl group or a heterocyclic group. Each of these hydrocarbon residue, acyl group and heterocyclic group may optionally be substituted.

5 Examples of the group bonded through a sulfur atom of R^1 , R^2 and R^{12} include a group of the formula: $-S(O)_t-R^{18}$, wherein R^{18} is a hydrogen atom, a hydrocarbon residue or a heterocyclic group, and t denotes an integer of 0 to 2. Each of these hydrocarbon residue and heterocyclic group may be optionally substituted.

10 Examples of the group bonded through a hetero atom includes a group bonded through a nitrogen atom, a group bonded through an oxygen atom and a group bonded through a sulfur atom. Those groups are the same as defined in R^1 and R^2 .

15 The hydrocarbon residue in the hydrocarbon residue which may be optionally substituted and the hydrocarbon residue-oxy group which may optionally be substituted described above includes a hydrocarbon residue having one to 20 carbon atoms. As examples of the C_{1-20} hydrocarbon residue, mention is made of (1) C_{1-15} alkyl, e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, etc, and among others, with C_{1-10} alkyl or C_{1-6} alkyl being preferable; (2) C_{3-10} cycloalkyl, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, etc, and among others, with C_{3-6} cycloalkyl being preferable; (3) C_{2-10} alkenyl, e.g. vinyl, allyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methylallyl, butadienyl, hexatrienyl, 3-octenyl, etc, and among others, with C_{2-6} alkenyl being preferable, (4) C_{2-10} alkynyl, e.g. ethynyl, 2-propynyl, isopropynyl, butynyl, t-butynyl, 3-hexynyl, etc, and among others,

with C₂₋₆ alkynyl being preferable; (5) C₃₋₁₀ cycloalkenyl, e.g. cyclopropenyl, cyclopentenyl, cyclohexenyl, etc, among others, with C₃₋₆ cycloalkenyl being preferable; (6) C₆₋₁₄ aryl e.g. phenyl, 1- or 2-naphthyl, anthryl, phenanthryl, acenaphthyl, anthracenyl, etc., among others, with phenyl and naphthyl, being preferable; and (7) C₇₋₂₀ aralkyl, e.g. benzyl, phenethyl, benzhydryl, trityl, etc, and among others, with benzyl and phenethyl being preferable.

10 The substituents which said hydrocarbon residue may optionally have include (1) halogen, (2) nitro, (3) nitroso, (4) cyano, (5) a hydroxyl group which may optionally be substituted by (i) C₁₋₆ alkyl, which may optionally be substituted by hydroxyl, C₁₋₆ alkoxy, C₁₋₃ alkoxy-C₁₋₃ alkoxy, C₁₋₃ alkylthio, hydroxy-C₁₋₃ alkoxy, C₁₋₆ alkyl-carbonyl, carboxyl, carbamoyl, C₁₋₆ alkyl-carbamoyl, 5 to 7 membered nitrogen containing heterocyclic group or halogen, (ii) C₁₋₄ acyl, (iii) C₇₋₂₀ aralkyl, which may optionally be substituted by 20 halogen, C₁₋₃ alkoxy or C₁₋₄ alkyl, (iv) C₆₋₁₄ aryl, which may optionally be substituted by halogen, (v) C₂₋₆ alkenyl, (vi) C₃₋₇ cycloalkyl, (vii) C₁₋₃ alkoxy-carbonyl, (viii) mono- or di-C₁₋₆ alkyl-amino, (ix) C₇₋₆ alkenyl-amino, (x) C₁₋₃ alkoxy-carbonyl, (xi) C₁₋₆ alkyl-carbonyl, (xii) C₃₋₆ cycloalkyl-oxycarbonyl or (xiii) 25 trifluorosulfonyl, (6) a group of the formula: -S(O)_f-R²¹, wherein f is an integer of 0 to 2, R²¹ represents a hydrogen atom or a hydrocarbon residue which may optionally be substituted, the hydrocarbon residue has 30 the same meaning as defined above, among others, C₁₋₂₀ alkyl especially C₁₋₆ alkyl, C₆₋₁₄ aryl, C₇₋₂₀ aralkyl are preferable, and as examples of the substituent to the hydrocarbon residue, mention is made of halogen, nitro, cyano, hydroxy, oxo, thioxo, carboxyl, cyano-C₆₋₁₄ aryl, 35 halogeno-C₆₋₁₄ aryl, etc, (7) an optionally substituted

amino group, which is represented by the formula: -
NR²²R²³, wherein each of R²² and R²³ independently are
hydrogen, C₁₋₆ alkyl, C₁₋₆ acyl or a 5 to 8 membered
heterocyclic group which is mentioned below or a group
5 bonded through nitrogen atom as described above, (8) a
group of the formula: -CO-R²⁴ wherein R²⁴ denotes (i)
hydrogen, (ii) hydroxyl, (iii) C₁₋₁₀ alkyl, (iv) C₁₋₆
alkoxy which may be substituted with C₆₋₁₄ aryl which
may optionally be substituted with halogen or nitro,
10 (v) C₃₋₆ cycloalkyl, (vi) C₆₋₁₄ aryl, (vii) C₆₋₁₄ aryloxy,
(viii) C₇₋₂₀ aralkyl, (ix) an optionally substituted
amino group which is defined (7) above or (x) an
optionally substituted 5- to 8-membered heterocyclic
group which is mentioned below, especially, C₁₋₁₀ acyl
15 is preferable, (9) a 5- through 8-membered heterocyclic
group containing 1-4 hetero-atom(s) selected from
oxygen (O), sulfur (S) and nitrogen (N) as ring
members, the heterocyclic group being optionally
substituted by (i) halogen, (ii) C₁₋₄ alkyl, (iii) C₁₋₃
20 alkoxy, (iv) C₁₋₄ alkylthio, (v) phenoxy which may
optionally be substituted by a halogen, (10) sulfo,
(11) C₆₋₁₄ aryl, e.g. phenyl, naphthyl, anthryl,
phenanthryl, acenaphthyl, anthracenyl, etc, which may
optionally be substituted with one to 4 of (a)
25 hydroxyl, (b) amino, (c) mono- or di-C₁₋₆ alkylamino,
e.g. methylamino, ethylamino, propylamino,
dimethylamino, diethylamino, etc, (d) C₁₋₆ alkoxy, e.g.
methoxy, ethoxy, propoxy, hexyloxy, etc) or (e)
halogen, (12) C₃₋₇ cycloalkyl, (13) C₁₋₆ alkylenedioxy,
30 e.g. methylenedioxy, ethylenedioxy, propylenedioxy,
2,2-dimethylenedioxy, etc, (14) oxo, (15) thioxo, (16)
C₂₋₄ alkynyl, (17) C₃₋₁₀ cycloalkyl, (18) C₂₋₁₀ alkenyl,
e.g. vinyl, allyl, isopropenyl, 1-butenyl, 2-butenyl,
butadienyl, hexatrienyl, etc., and among others, C₂₋₆
35 alkenyl is preferable (19) C₇₋₂₀ aralkyl, which has the

same meaning as defined above, (20) amidino, and (21) azido.

The above substituents on the hydrocarbon residue may further have substituents. Such substituents includes (1) hydroxy, (2) amino, (3) mono- or di-C₁₋₄ alkyl-amino, e.g. methylamino, ethylamino, propylamino, dimethylamino, diethylamino, etc), (4) C₁₋₄ alkoxy, e.g. methoxy, ethoxy, propoxy, etc, (5) halogen and (6) nitro. The number of the substituents is preferably 1 to 4, and more preferably 1 to 2.

When the above optionally substituted hydrocarbon residue is cycloalkyl, cycloalkenyl, aryl or aralkyl, each of the group may have one to three of C₁₋₆ alkyl, e.g. methyl, ethyl, propyl, isopropyl, butyl, as a substituent. The C₁₋₆ alkyl group may further substituted by one to three of hydroxy, oxo, C₁₋₃ alkoxy, e.g. methoxy, ethoxy, n-propoxy, isopropoxy, C₁₋₃ alkylthio, halogen or carbamoyl.

As examples of the substituted alkyl, mention is made of (1) formyl, i.e. methyl is substituted by oxo, (2) carboxyl, i.e. methyl is substituted by oxo and hydroxy, (3) C₁₋₆ alkoxy-carbonyl, i.e. methyl is substituted by oxo and alkoxy, e.g. methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, (4) hydroxy-C₁₋₆ alkyl, e.g. hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, (5) C₁₋₃ alkoxy-C₁₋₆ alkyl, e.g. methoxymethyl, ethoxyethyl, ethoxybutyl, propoxymethyl, propoxyhexyl.

In the above optionally substituted hydrocarbon residue, the number of the substituent(s) is preferably 1 to 6, more preferably 1 to 5, still more preferably 1 to 3 and most preferably 1 to 2. The number of the substituent(s) which is substituted on the substituent is preferably 1 to 3, more preferably 1 or 2.

As the acyl group in the optionally substituted

acyl group, mention is made of an acyl group which is derived from C₁₋₂₄ aliphatic carboxylic acid.

Further examples of the acyl group include formyl, C₁₋₆ alkyl-carbonyl, e.g. acetyl, ethylcarbonyl, propylcarbonyl, tert-propylcarbonyl, C₁₋₆ alkoxy-carbonyl, e.g. methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, C₆₋₁₄ aryl-carbonyl, e.g. benzoyl), C₆₋₁₄ aryloxy-carbonyl, e.g. phenoxycarbonyl, C₇₋₁₅ aralkyl-carbonyl, e.g. benzylcarbonyl), and C₇₋₁₉ aralkyloxy-carbonyl (e.g. benzyloxycarbonyl). Among others, C₁₋₁₀ acyl is preferable. As substituents in the optionally substituted acyl, mention is made of these in the optionally substituted hydrocarbon residue. The substituents on the C₁₋₁₀ acyl group are the same as those on the hydrocarbon residue.

Examples of the optionally substituted carbamoyl group include a carbamoyl group which may optionally be substituted by an optionally substituted C₁₋₂₀ hydrocarbon residue. As an optionally substituted C₁₋₂₀ hydrocarbon residue, mention is made of those described hereinbefore. Concrete examples of the substituted carbamoyl include mono- or di-C₁₋₁₅ alkyl-carbamoyl, e.g. methylcarbamoyl, ethylcarbamoyl, hexylcarbamoyl, dimethylcarbamoyl, methylethylcarbamoyl. The substituents on the carbamoyl group are the same as those on the hydrocarbon residue.

As the heterocyclic group in the optionally substituted heterocyclic group which bonds with the constitutive carbon atom, mention are made of 5 to 8 membered heterocyclic groups which have one to 4 hetero atoms selected from an oxygen atom, sulfur atom and nitrogen atom than carbon atom; and two ring or three ring condensed-ring heterocyclic groups composed of the above heterocyclic group and other ring groups.

Examples of the heterocyclic groups include (1) 5-

membered cyclic groups containing, besides the carbon atom, 1 to 4 hetero-atoms selected from an oxygen atom, sulfur atom and nitrogen atom, such as thienyl, furyl, pyrrolyl, pyrrolinyl, oxazolyl, thiazolyl, pyrazolyl, imidazolyl, imidazolyl, isoxazolyl, isothiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, furazanyl, 1,2,4-thiadiazolyl, 1,2,3-thiadiazolyl, 1,2,5-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, triazinyl, triazolidinyl, and 1H- or 2H-tetrazolyl; (2) 6-membered cyclic groups containing, besides, carbon atom, 1 to 4 hetero-atoms selected from an oxygen atom, sulfur atom and nitrogen atom, as exemplified by pyridyl, pyrimidinyl, thiomorpholinyl, morpholinyl, triazinyl, pyrrolidinyl, piperazinyl, piperidinyl, pyranyl, thiopyranyl, 1,4-oxadiazolyl, 1,4-thiazinyl, 1,3-thiazinyl, triazinyl, oxotriazinyl, pyridazinyl and pyrazinyl. (3) bicyclic or tricyclic condensed ring groups containing, besides carbon atom, 1 to 4 hetero-atoms selected from oxygen atom, sulfur atom and nitrogen atom, as exemplified by benzofuryl, benzothiazolyl, benzoxazolyl, tetrazolo[1,5-b]pyridazinyl, triazolo[4,5-b]pyridazinyl, benzoimidazolyl, quinolyl, isoquinolyl, cinnolinyl, phthaladinyl, quinazolinyl, quinoxalinyl, indolidinyl, indolyl, quinolidinyl, 1,8-naphthylidinyl, purinyl, pteridinyl, dibenzofuranyl, carbazolyl, acridinyl, phenanthridinyl, chromanyl, benzoxadinyl, phenazinyl, phenothiazinyl and phenoxazinyl.

Examples of the substituents, which the heterocyclic group may have include (1) C₁₋₆ alkyl, (2) C₂₋₆ alkenyl, (3) C₂₋₆ alkynyl, (4) C₃₋₆ cycloalkyl, (5) C₅₋₇ cycloalkenyl, (6) C₇₋₁₁ aralkyl, (7) C₆₋₁₄ aryl, (8) C₁₋₆ alkoxy, (9) C₆₋₁₄ aryloxy, e.g. phenoxy, (10) C₁₋₆ alkanoyl, e.g. formyl, acetyl, propionyl, n-butyryl and isobutyryl, (11) C₆₋₁₄ aryl-carbonyl, e.g. benzoyl, (12) C₁₋₆ alkanoyloxy, e.g. formyloxy, acetyloxy,

propionyloxy, n-butyryloxy and iso-butyryloxy, (13) C₆₋₁₄ aryl-carbonyloxy, e.g. benzoyloxy), (14) carboxyl, (15) C₁₋₆ alkoxy-carbonyl, e.g. methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, iso-propoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl and tert-butoxycarbonyl, (16) carbamoyl, (17) N-mono-C₁₋₄ alkylcarbamoyl, e.g. N-methylcarbamoyl, N-ethylcarbamoyl, N-propylcarbamoyl, N-isopropylcarbamoyl and N-butylcarbamoyl, (18) N,N-di-C₁₋₄ alkylcarbamoyl (e.g. N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N,N-dipropylcarbamoyl and N,N-dibutylcarbamoyl), (19) cyclic aminocarbonyl, e.g. 1-aziridinylcarbonyl, 1-azetidiny carbonyl, 1-pyrrolidinylcarbonyl, 1-piperidinylcarbonyl, N-methylpiperazinylcarbonyl and morpholinocarbonyl, (20) halogen, (21) mono- or tri-halogeno-C₁₋₄ alkyl, e.g. chloromethyl, dichloromethyl, trifluoromethyl and trifluoroethyl, (22) oxo, (23) amidino, (24) imino, (25) amino, (26) mono- or di C₁₋₄ alkylamino, e.g. methylamino, ethylamino, propylamino, isopropylamino, butylamino, dimethylamino, diethylamino, dipropylamino, diisopropylamino and dibutylamino, (27) 3- to 6-membered cyclic amino group containing, besides the carbon atom and one nitrogen atom, 1 to 3 hetero-atoms selected from oxygen atom, sulfur atom and nitrogen atom, e.g. aziridinyl, azetidiny, pyrrolidinyl, pyrrolinyl, pyrrolyl, imidazolyl, pyrazolyl, imidazolidinyl, piperidino, morpholino, dihydropyridyl, N-methylpiperazinyl and N-ethylpiperazinyl, (28) C₁₋₆ alkanoylamino, e.g. formamido, acetamido, trifluoroacetamido, propionylamido, butyrylamido and isobutyrylamido, (29) benzamido, (30) carbamoylamino, (31) N- C₁₋₄ alkylcarbamoylamino, e.g. N-methylcarbamoylamino, N-ethylcarbamoylamino, N-propylcarbamoylamino, N-isopropylcarbamoylamino and N-butylcarbamoylamino, (32)

N,N-di-C₁₋₄ alkylcarbamoylamino, e.g. N,N-dimethylcarbamoylamino, N,N-diethylcarbamoylamino, N,N-dipropylcarbamoylamino and N,N-dibutylcarbamoylamino, (33) C₁₋₃ alkylenedioxy (e.g. methylenedioxy and ethylenedioxy, (34) -B(OH)₂, (35) hydroxyl, (36) epoxy (-O-), (37) nitro, (38) cyano, (39) mercapto, (40) sulfo, (41) sulfino, (42) phosphono, (43) dihydroxyboryl, (44) sulfamoyl, (45) C₁₋₆ alkylsulfamoyl (e.g. N-methylsulfamoyl, N-ethylsulfamoyl, N-propylsulfamoyl, N-isopropylsulfamoyl and N-butylsulfamoyl), (46) di-C₁₋₆ alkylsulfamoyl, e.g. N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N,N-dipropylsulfamoyl and N,N-dibutylsulfamoyl), (47) C₁₋₆ alkylthio, e.g. methylthio, ethylthio, propylthio, isopropylthio, n-butylthio, sec-butylthio and tert-butylthio, (48) phenylthio, (49) C₁₋₆ alkylsulfinyl, e.g. methylsulfinyl, ethylsulfinyl, propylsulfinyl and butylsulfinyl), (50) phenylsulfinyl, (51) C₁₋₆ alkylsulfonyl, e.g. methylsulfonyl, ethylsulfonyl, propylsulfonyl and butylsulfonyl, and (52) phenylsulfonyl. The number of the substituents ranges from 1 to 6, preferably 1 to 3.

Examples of the above-mentioned optionally substituted heterocyclic groups which bond through a carbon atom include 5- to 8-membered cyclic groups or condensed ring thereof containing, besides carbon atom, 1 to 4 hetero-atoms such as oxygen atom, sulfur atom and nitrogen atom. Examples of (1) 5-membered cyclic groups containing, besides carbon atom, 1 to 4 hetero-atoms selected from oxygen atom, sulfur atom and nitrogen atom which bond through a carbon atom include 2- or 3-thienyl, 2- or 3-furyl, 2- or 3-pyrrolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-pyrazolyl, 2- or 3-pyrrolidinyl. 2-, 4- or 5-imidazolyl, 2-imidazolinyl, 2-imidazolidinyl, 3, 4- or

5-isoxazolyl, 3-, 4- or 5-isothiazolyl, 3- or 5-(1,2,4-oxadiazolyl), 2-, 5- or 6-(1,3,4-oxadiazolyl), 3- or 5-(1,2,4-thiadiazolyl), 2- or 5-(1,3,4-thiadiazolyl), 4- or 5-(1,2,3-thiadiazolyl), 3- or 4-(1,2,5-thiadiazolyl), 2- or 5-(1,2,3-triazolyl), 3- or 5-(1,2,4-triazolyl), and 5-(1H- or 2H-tetrazolyl).
Examples of 6-membered cyclic groups containing, besides, carbon atom, 1 to 4 hetero-atoms selected from oxygen atom, sulfur atom or nitrogen atom which bond through a carbon atom include 2-, 3- or 4-pyridyl, 2-, 4- or 5-pyrimidinyl, 2- or 3-thiomorpholinyl, 2- or 3-morpholinyl, 3- or 6-triazinyl, 2-, 3- or 4-piperidinyl, 2- or 3-piperazinyl, 2- or 3-pyranyl, 2- or 3-thiopyranyl, 2- or 3-(1,4-oxadiazinyl), 2- or 3-(1,4-thiazinyl), 1- or 4-(1,3-thiazinyl), 3- or 6-triazinyl, 3- or 4-pyridazinyl, 2- or 3-pyrazinyl and 3- or 4-pyridazinyl. Examples of bicyclic or tricyclic condensed ring groups containing, besides carbon atom, 1 to 4 hetero-atoms selected from oxygen atom, sulfur atom and nitrogen atom which bonds through a carbon atom include benzofuryl, benzothiazolyl, benzoxazolyl, tetrazolo[1,5-b]pyridazinyl, triazolo[4,5-b]pyridazinyl, benzoimidazolyl, quinolyl, isoquinolyl, cinnolinyl, phthaladinyl, quinazolinyl, quinoxalinyl, indolidinyl, indolyl, quinolidinyl, 1,8-naphthylidinyl, purinyl, pteridinyl, dibenzofuranyl, carbazolyl, acridinyl, phenanthridinyl, chromanyl, benzoxadinyl, phenazinyl, phenothiazinyl and phenoxazinyl. The substituents on the heterocyclic groups which bond through a carbon atom are the same as those on the heterocyclic group above-mentioned.

As examples of the 5 to 7 membered cyclic amino groups containing nitrogen atom, i.e. cyclic amino group or nitrogen atom-containing heterocyclic group, mention is made of pyrrolidinyl, pyrrolinyl, pyrrolyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, imidazolidinyl,

imidazolinyl, imidazolyl, 1,2,3-triazinyl, 1,2,3-triazolidinyl, 1,2,3-triazolyl, 1,2,3,4-tetrazolyl, piperidinyl, piperazinyl, azepinyl, hexamethyleneamino, oxazolidino, morpholino, thiazolidino or
5 thiomorpholino. As more preferable cyclic amino groups, mention is made of pyrrolidinyl, pyrazolinyl, pyrazolyl, piperidinyl, piperazinyl, morpholino and thiomorpholino.

The cyclic amino groups may be substituted. The
10 examples of the substituents includes (1) C₁₋₆ alkyl, (2) C₆₋₁₄ aryl, (3) C₇₋₁₀ aralkyl, (4) benzhydryl, (5) C₁₋₆ alkyl-carbonyl, (6) C₆₋₁₄ aryl-carbonyl, (7) C₁₋₆ alkoxy-carbonyl. As the preferable substituent, mention is made of C₁₋₆ alkyl, preferably C₁₋₃ alkyl.

15 Examples of the homocyclic group in the optionally substituted homocyclic groups shown by R³ include 3- to 7-membered cyclic hydrocarbon groups consisting of carbon atoms, for example, C₆₋₁₀ aryl, e.g. phenyl, naphthyl; C₃₋₇ cycloalkyl, e.g. cyclopropyl, cyclobutyl,
20 cyclopentyl, cyclohexyl and cycloheptyl; and C₃₋₇ cycloalkenyl, e.g. cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl and cycloheptenyl.

Examples of the substituents which the said homocyclic groups may have, include (1) C₁₋₁₅ alkyl (and
25 among others C₁₋₆ alkyl being preferable) which may optionally be substituted by a halogen, (2) C₃₋₁₀ cycloalkyl, (3) C₂₋₁₀ alkenyl, (4) C₂₋₁₀ alkynyl, (5) C₃₋₁₀ cycloalkyl, (6) C₆₋₁₀ aryl, (7) C₇₋₂₀ aralkyl, (8) nitro, (9) hydroxyl, (10) mercapto, (11) oxo, (12) thioxo,
30 (13) cyano, (14) carbamoyl, (15) carboxyl, (16) C₁₋₆ alkoxy-carbonyl (e.g. methoxycarbonyl and ethoxycarbonyl), (17) sulfo, (18) halogen, (19) C₁₋₆ alkoxy, (20) C₆₋₁₀ aryloxy, e.g. phenoxy, (21) C₁₋₆ acyloxy, e.g. acetoxy, propionyloxy, (22) C₁₋₆
35 alkylthio, e.g. methylthio, ethylthio, n-propylthio,

isopropylthio, n-butylthio and t-butylthio, (23) C₆₋₁₀ arylthio, e.g. phenylthio), (24) C₁₋₆ alkylsulfinyl, e.g. methylsulfinyl and ethylsulfinyl, (25) C₆₋₁₀ arylsulfinyl, e.g. phenylsulfinyl, (26) C₁₋₆ alkylsulfonyl, e.g. methylsulfonyl and ethylsulfonyl, (27) C₆₋₁₀ arylsulfonyl, e.g. phenylsulfonyl, (28) amino, (29) C₁₋₆ acylamino, e.g. acetylamino and propylamino, (30) mono- or di- C₁₋₄ alkylamino, e.g. methylamino, ethylamino, n-propylamino, isopropylamino, n-butylamino, dimethylamino and diethylamino, (31) C₁₋₈ cycloalkylamino, e.g. cyclopropylamino, cyclobutylamino, cyclopentylamino and cyclohexylamino, (32) C₆₋₁₀ arylamino, e.g. anilino, (33) C₁₋₆ alkanoyl, e.g. formyl, acetyl and hexanoyl), (34) C₁₋₆ alkanoyloxy, e.g. acetyloxy, propionyloxy, (35) C₆₋₁₀ aryl-carbonyl, e.g. benzoyl, and (36) 5- to 6-membered heterocyclic groups containing, besides carbon atom, 1 to 4 hetero-atoms selected from oxygen, sulfur and nitrogen (e.g. 2- or 3-thienyl, 2- or 3-furyl, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-imidazolyl, 1,2,3- or 1,2,4-triazolyl, 1H or 2H-tetrazolyl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-pyrimidyl, 3- or 4-pyridazinyl, quinolyl, isoquinolyl and indolyl. The number of substituents ranges from 1 to 6, preferably from 1 to 3, more preferably from 1 to 2.

In the compound (I), preferred examples of R¹ are a group bonded through a carbon atom or a group bonded through a nitrogen atom. As the group bonded through a carbon atom, mention is made of an optionally substituted C₁₋₂₀ hydrocarbon residue, especially, an optionally substituted C₁₋₁₀ alkyl group or an optionally substituted C₁₋₆ alkyl group. As substituents in the optionally substituted C₁₋₂₀

hydrocarbon residue of R^1 , mention is made of (1) halogen, (2) nitro, (3) cyano, (4) an optionally substituted amino, (5) an optionally substituted hydroxyl group, (6) a group of the formula: $-S(O)_t-R^6$ (wherein t denotes an integer of 0 to 2, and R^6 is a hydrogen atom or an optionally substituted hydrocarbon residue.)

A more preferable example of R^1 is substituted amino-alkyl such as N,N-disubstituted aminoalkyl. The most preferable example of R^1 is N-aralkyl-N-alkylaminoalkyl, especially N- C_{7-11} aralkyl-N- C_{1-6} alkylamino- C_{1-6} alkyl.

As the preferable example of R^2 , mention is made of a group bonded through a carbon atom, especially an optionally substituted C_{1-20} hydrocarbon residue, more especially an optionally substituted C_{6-14} aryl group. As the preferable examples of the substituents, mention is made of (1) an optionally substituted amino, (2) an optionally substituted hydroxyl group, (3) an optionally substituted carbamoyl, (4) an optionally substituted carboxyl, (5) an optionally substituted alkenyl, (5) acyl or (6) nitro.

The preferable substituents in the optionally substituted aryl, include (1) an alkoxy group, (2) an alkylcarbonyl group, (3) an alkylaminocarbonyl group, (4) an optionally substituted alkenyl, whose preferable substituent includes alkylcarbonyl or alkylaminocarbonyl, or (5) an optionally substituted amino, whose preferable substituent includes an alkyl group or an alkyl group which is substituted by alkanoyl, alkanoyl or hydroxy. Especially, an alkanoylamino group or an alkoxy group is more preferable.

As the preferable group of R^2 , mention is made of a C_{6-14} aryl group which may optionally be substituted

with a group selected from the group consisting of (i) nitro, (ii) C₁₋₆ alkoxy and (iii) amino which may optionally be substituted C₁₋₆ alkanoyl.

5 As the preferable example of R³, mention is made of an optionally substituted homo-cyclic group, more preferably, an optionally substituted C₆₋₁₄ aryl group.

The substituents in the optionally substituted homo-cyclic group, mention is made of (1) halogen, (2) nitro, (3) an optionally substituted hydroxyl group,
10 (4) a group of the formula: -S(O)t-R⁶ (wherein t denotes an integer of 0 to 2, and R⁶ is a hydrogen atom or an optionally substituted hydrocarbon residue).

As more preferable group of R³, mention is made of an aryl group substituted by one or two halogens. As
15 the aryl group, phenyl is most preferable. The most preferable group of R³ is a phenyl group substituted by fluorine.

As the preferable example of the heterocyclic group in the optionally substituted heterocyclic group
20 of R⁴, mention is made of an optionally substituted 3- to 8-membered heterocyclic group, especially an optionally substituted 5- to 8-membered heterocyclic group having at a least one nitrogen atom in a ring, and more preferably 5- to 6-membered heterocyclic group
25 having at least one nitrogen atom in a ring. As the preferred examples of the heterocyclic ring, mention is made of oxazolyl, isoxazolyl, thiazolyl, imidazolyl, triazolyl, oxoimidazolyl, thiazinyl. Among others, isoxazoly is most preferred.

30 Preferred examples of the substituent to the heterocyclic group are (1) halogen, (2) nitro, (3) an optionally substituted hydroxyl group, (4) a group of the formula: -S(O)m-R⁶ (wherein m denotes an integer of 0 to 2, and R⁶ is a hydrogen atom or an optionally
35 substituted hydrocarbon residue), (5) an optionally

substituted amino, or (6) a C₁₋₁₀ hydrocarbon residue.

Preferred examples of the substituents on the optionally substituted amino group, the optionally substituted hydroxyl group or the optionally substituted mercapto group of R⁴ are (1) C₁₋₁₀ hydrocarbon residue which may optionally be substituted by C₁₋₆ alkoxy-carbonyl or carbamoyl, (2) C₁₋₁₀ acyl group, or (3) a group of the formula: -S(O)_t-R⁶, wherein t denotes an integer of 0 to 2, and R⁶ is a hydrogen atom or an optionally substituted hydrocarbon residue.

Preferably R⁴ is (1) a 5- or 6-membered heterocyclic group which has one nitrogen atom and one oxygen atom and which is bonded through a carbon atom, (2) a hydroxyl group which may optionally be substituted with a group selected from the group consisting of (i) C₁₋₆ alkyl which may optionally be substituted with C₁₋₆ alkoxycarbonyl or carbamoyl, (ii) C₁₋₆ alkanoyl and (iii) C₁₋₆ alkylsulfonyl, (3) a group of the formula: -S(O)_t-R^{6'}, wherein t is an integer of 0 to 2 and R^{6'} is C₁₋₆ alkyl, or (4) an amino group which may optionally be substituted with C₁₋₆ alkanoyl.

As the group R⁵, a hydrogen atom or a hydrocarbon residue is preferable, especially, a hydrogen atom or C₁₋₂₀ hydrocarbon atom is more preferable. Among others, hydrogen atom or C₁₋₁₀ alkyl is more preferable. Hydrogen atom is most preferable.

In the formula (I), n is preferably 1.

In the above definitions, as the examples of halogen, mention is made of fluorine, chlorine, bromine, iodine.

As examples of C₁₋₆ alkyl, mention is made of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl. C₁₋₄ alkyl is exemplified by methyl, ethyl, n-

propyl, isopropyl, n-butyl, isobutyl, t-butyl. C_{1-3} alkyl is exemplified by methyl, ethyl, n-propyl, isopropyl.

5 As examples of C_{2-10} alkenyl, mention is made of vinyl, allyl, 2-methylallyl, isopropenyl, 2-butenyl, 3-butenyl, butadienyl, hexatrienyl, 3-octenyl. Examples of C_{2-6} alkenyl are vinyl, allyl, isopropenyl, butenyl and hexatrienyl. Examples of C_{2-4} alkenyl are vinyl, allyl, isopropenyl and butenyl.

10 As example of the C_{2-10} alkynyl, mention is made of ethynyl, 1-propynyl, 2-propynyl, propargyl, and 3-hexynyl. C_{2-6} alkynyl and C_{2-4} alkynyl is exemplified by ethynyl, 1-propynyl, 2-propynyl.

15 C_{3-10} cycloalkyl is exemplified by cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl. C_{3-8} cycloalkyl is exemplified by cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl. C_{3-7} cycloalkyl is exemplified by cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl. C_{3-6} cycloalkyl is exemplified by cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.

20 Examples of C_{3-7} cycloalkenyl are cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, and examples of C_{5-7} cycloalkenyl are cyclopentenyl, cyclohexenyl.

25 C_{6-14} aryl is exemplified by phenyl, naphthyl, anthryl, phenanthryl, acenaphthyl, anthracenyl. Examples of C_{6-10} aryl are phenyl and naphthyl. Especially phenyl is most preferable.

30 C_{7-20} aralkyl is exemplified by benzyl and phenethyl, benzhydryl, trithyl. C_{7-15} aralkyl and C_{7-11} aralkyl are benzyl, phenethyl, benzhydryl. Examples of C_{7-11} aralkyl and C_{7-10} aralkyl are benzyl, α -methylkenyl and phenethyl.

35 C_{1-6} alkoxy is exemplified by methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, isobutoxy, s-butoxy, t-

butoxy, pentyloxy, isopentyloxy, neopentyloxy, hexyloxy, C₁₋₄ alkoxy is exemplified by methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, isobutoxy, s-butoxy, t-butoxy. C₁₋₃ alkoxy is exemplified by methoxy, ethoxy, propoxy, isopropoxy.

C₁₋₆ acyl is exemplified by a C₁₋₆ alkanoyl group of the formula: -CO-R²⁵, wherein R²⁵ is hydrogen, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, s-butyl, t-butyl, pentyl.

C₁₋₄ acyl is exemplified by a C₁₋₄ alkanoyl group of the formula: -CO-R^{25'}, wherein R^{25'} is hydrogen, methyl, ethyl, propyl, isopropyl.

Preferable five to seven-membered heterocyclic groups which contain 1 to 4 heteroatoms of oxygen, sulfur or nitrogen are exemplified by thienyl, furyl, pyrrolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, triazolyl, tetrazolyl, furazanyl, tetrahydrofuryl, pyridyl, pyrimidinyl, pyridazynyl, oxadiazolyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, pyrrolinyl, pyrazolidinyl, pyrazolinyl, imidazolidinyl, imidazolinyl, imidazolyl, 1,2,3-triazinyl, 1,2,3-triazolidinyl, 1,2,3-triazolyl, 1,2,3,4-tetrazolyl, piperidinyl, piperazinyl, hexamethyleneaminyl, oxazolidinyl or thiazolidinyl. As more preferable heterocyclic groups, mention is made of 5 to 6 membered heterocyclic groups. In particular, pyrrolidinyl, pyrazolinyl, pyrazolyl, piperidinyl, piperazinyl, morpholinyl and thiomorpholinyl are preferable.

Examples of optionally substituted aromatic hydrocarbon or heterocyclic residues optionally containing a hetero-atom, which are represented by A and B, include aromatic hydrocarbon residues such as phenyl, and 4- to 7-membered monocyclic or condensed heterocyclic residues containing one or more of N, S and O, for example, pyridyl, pyrimidinyl, pyridazinyl,

pyrazinyl, thienyl, furyl, pyrrolyl, imidazolyl,
 pyrazolyl, isothiazolyl, isooxazolyl, benzofuranyl,
 isobenzofuranyl, indoliziny, isoindolyl, 3H-indolyl,
 indolyl, 1H-indazolyl, purinyl, 4H-quinoliziny,
 5 isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl,
 quinoxalinyl, quinazolinyl, cinnolinyl and pteridinyl
 (preferably phenyl). As the spacer, any one can be
 exemplified, so long as it is a divalent chain in which
 the number of atoms constituting the straight chain is
 10 1 or 2, and it may have a side chain, more
 specifically, lower (1-4C) alkylene, -CO-, -O-, -S-, -
 NH-, -CO-NH-, -O-CH₂-, -S-CH₂-, and -CH=CH-.

R⁷ is an optionally substituted 5-7 membered
 heterocyclic residue having, as a group capable of
 15 constituting the ring, carbonyl group, thiocarbonyl
 group, an optionally oxidized sulfur atom or a group
 convertible into them. Examples of the group R⁷ are
 2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl, 2,5-dihydro-5-
 thioxy-1,2,4-oxadiazol-3-yl, 2,5-dihydro-5-oxo-1,2,4-
 20 thiadiazol-3-yl. (As to the R⁷, D, A ring, B ring,
 refer European Patent Application Publication No.
 520423A).

The compound of the following formula:



wherein R¹, R², R³, R⁴, R⁵ and n have the same meaning
 30 defined as above, can be produced by per se known
 methods, have a similar activity and can be used in a
 similar way.

The present compound (I), and its salts can be
 produced easily by per se known methods, as exemplified
 35 by the following production methods.

Production Method 1:


Production of the nucleus of the present compound:

In accordance with the method disclosed by K. Gewald, E. Schinke and H. Böttcher, Chem. Ber., 99, 94-100 (1966), and as illustrated in Scheme 1, infra, an
5 adequate ketone or aldehyde having an active methylene (i) was allowed to react with a cyanoacetic acid ester derivative and sulfur to convert it into a 2-aminothiophene derivative (ii). More specifically, in the case of using ketone ($R^{1'} \neq H$), it is subjected to
10 heating under reflux together with a cyanoacetic acid ester derivative, in the presence of acetic acid and ammonium acetate, in a proper solvent such as toluene to give an alkylidene cyanoacetic acid ester derivative, which is then heated in an adequate
15 solvent, for example, ethanol in the presence of sulfur and a base to afford a 2-aminothiophene derivative (ii). And, in the case of using aldehyde ($R^{1'} = H$), it is heated in a proper solvent, for example, dimethylformamide, in the presence of a cyanoacetic
20 acid ester derivative, sulfur and a base to give a 2-aminothiophene derivative (ii). The compound (ii) thus obtained is heated, in accordance with the method disclosed by Kuwata et al. [cf. German Patent 2,435,025], with diethyl ethoxymethylenemalonate to
25 give an adduct (iii). The adduct is stirred in an appropriate solvent, i.e. one which does not adversely affect the reaction, e.g. alcohols such as ethanol and methanol, in the presence of a base, e.g. alkali metal hydroxide such as potassium hydroxide and sodium
30 hydroxide, at temperatures ranging from about 10 to 70°C to give thiophene carboxylic acid derivative (iv). Then, the thiophene carboxylic acid derivative (iv) thus obtained is subjected to ring-closure by heating in polyphosphoric acid ester (PPE) to give a
35 thieno[2,3-b]pyridine derivative (v). The compound (v) is stirred in an appropriate solvent, e.g. amides such

as dimethylformamide and dimethylacetamide), in the presence of a compound of the formula: $Xa-(CH_2)_n-R^3$, wherein Xa is a halogen atom, n and R^3 have the same meaning as defined above, and a base, e.g. an organic base such as pyridine and triethylamine) at temperatures ranging from about 10 to 100°C to give a 4,7-dihydro-4-oxothieno[2,3-b]pyridine-5-carboxylic acid ester derivative shown by the formula (vi).

The foregoing production method is shown in Scheme 1. In the Scheme 1, $R^{1''}$ denotes C_{1-6} alkyl or a hydrogen atom, R' denotes C_{1-6} alkyl, Xa denotes a halogen atom, and Et denotes ethyl. The groups R^2 , R^3 , R^5 and n have the same meaning as defined above. As the examples of halogen of Xa , mention is made of fluorine, bromine, chlorine, iodine.

Scheme 1:



Production Method 2:

25 In substantially the same manner as in the Production Method 1, and as illustrated in Scheme 2, infra, a 2-aminothiophene derivative whose 5-position is unsubstituted (vii), which can be synthesized by the method disclosed by Karl Gewald, Chem. Ber., 98, 3571-3577 (1965); K. Gewald and E. Schinke, Chem. Ber., 99, 2712-2715 (1966) is allowed to react with diethyl


30 ethoxymethylene malonate under heating, in accordance with the method disclosed by Kuwata et al., German Patent 2,435,025, to give an adduct (viii). The adduct is stirred at temperatures ranging from about 10 to

35 60°C in an appropriate solvent, e.g. alcohols such as ethanol and methanol, in the presence of a suitable

base, e.g. alkali metal hydroxide such as potassium hydroxide and sodium hydroxide, to give thiophene carboxylic acid derivative (ix). To the compound (ix) the group $R^{2''}$ is introduced to give a compound (x). As
5 the reaction of the introduction of $R^{2''}$, mention is made of, for example, nitration using fuming nitric acid - concentrated sulfuric acid or sodium nitrate - concentrated sulfuric acid, acylation using acid chloride- aluminum chloride, formylation using
10 phosphorus oxychloride - dimethylformamide or N-methylformanilide and halogenation using N-bromosuccinimide or bromine-pyridine. Then the compound (x) is subjected to ring-closure reaction under heating in polyphosphoric acid ester (PPE) to
15 give a thieno[2,3-b]pyridine derivative (xi). The compound (xi) is subjected to the similar reaction of the compound (v) to the compound (vi) to give a compound (xii) wherein $R^{2''}$ is nitro group, an acyl group, a formyl group or halogen.

20 The foregoing method is shown in Scheme 2. In the Scheme 2, $R^{2''}$ denotes nitro group, acyl group, formyl group or halogen, and other groups have the same meaning as defined above.

Scheme 2:



Production Method 3:

20 Production of a compound having formyl at 5-position:

As illustrated in Scheme 3, *infra*, in an appropriate solvent, e.g. ethers such as tetrahydrofuran, ethyl ether and dioxane, 4,7-dihydro-4-oxothieno[2,3-b]pyridine-5-carboxylic acid ester derivative (v) is stirred together with a suitable reducing agent, e.g. lithium aluminum hydride, at a temperature ranging from about 0 to 80°C to give a reduced compound (xiii).


30 The compound (xiii) is reacted with a compound of the formula: $\text{Xa}-(\text{CH}_2)_n-\text{R}^3$, wherein Xa denotes a halogen atom, and n and R^3 have the same meaning as defined above, in an appropriate solvent, e.g. dimethylformamide, dimethylacetamide, at a temperature ranging from 10°C to 100°C under stirring to give 4,7-dihydro-4-oxothieno[2,3-b]pyridine derivative shown by

35

the formula (xiv). The said derivative is stirred, together with a suitable oxidizing agent, e.g. manganese dioxide, in a proper solvent, e.g. dichloromethane or chloroform, at temperatures ranging from about 10 to 80°C to give a 5-formyl derivative (xv).

The foregoing method is shown in Scheme 3. In the Scheme 3, the groups $R^{1''}$, Xa , R^2 , R^3 , R^5 and n have the same meaning defined above.

Scheme 3:



Production Method 4:


Production of 5-carbonyl derivative from 5-formyl derivative is illustrated in Scheme 4, infra:

35 The 5-formyl derivative (xv) is stirred, together with a Grignard's reagent of the formula: $R^{21}MgXa$,

wherein R^{21} denotes C_{1-6} alkyl and Xa denotes a halogen atom, at a temperature ranging from about 0 to 80°C in an appropriate solvent, e.g. ethers such as tetrahydrofuran and ethyl ether, to give a corresponding secondary alcohol derivative (xvi). The compound (xvi) is stirred, together with a suitable oxidizing agent, e.g. metal oxide such as manganese dioxide, in a proper solvent, e.g. halogenated hydrocarbons such as dichloromethane and chloroform, at a temperature ranging from about 10 to 80°C to give a 5-carbonyl derivative (xvii). The foregoing production method 4 is shown in Scheme 4:

In the Scheme 4, R^{21} denotes C_{6-14} aryl group, C_{1-6} alkyl group or an optionally substituted C_{1-6} alkyl group, and other groups have the same meaning defined above.

Scheme 4:



Production Method 5:

Production of 5-keto derivatives:


As illustrated in Scheme 5, *infra*, 4,7-Dihydro-4-oxothieno[2,3-b]pyridine-5-carboxylic acid ester derivative (xviii), which is produced by subjecting the

compound (vi) or (xii) to ester exchange reaction, is stirred at temperatures ranging from about 10 to 100°C, together with an aluminum amide derivative previously produced from a proper aluminum reagent, e.g. trimethyl aluminum and diisobutyl aluminum hydride (DIBAL) and amine in an appropriate suitable solvent, e.g. halogenated hydrocarbons such as dichloromethane and ethers such as tetrahydrofuran, ethyl ether and dioxane, to give a 4,7-dihydro-4-oxothieno[2,3-b]pyridine-5-carboxylic acid amide derivative (xix). The derivative (xix) is stirred, together with a Grignard's reagent, in an appropriate solvent, e.g. tetrahydrofuran and ethyl ether, at a temperature ranging from about -78°C to 80°C to give a corresponding ketone derivative (xx). The foregoing production method 5 is shown in Scheme 5:


In Scheme 5, R^{22} denotes C_{1-6} alkyl or C_{6-14} aryl, R^{23} and R^{24} respectively denotes a hydrogen atom or a group bonded through a carbon atom. R^{25} denotes a group bonded through a carbon atom. Other group have the same meaning as defined above.

Scheme 5:

35



10



15

(xx)

Production Method 6:

20 Production of a compound wherein it has an aryl group at 2-position is illustrated in Scheme 6, infra:

The compound (xxi), whose 2-position is halogen and which is produced by a similar manner in said Production Method 2, or which is produced by halogenating a compound wherein it has a hydrogen atom at its 2-position with N-bromosuccinimide or bromine-pyridine, is dissolved in an appropriate solvent, e.g. ethers such as 1,2-dimethoxyethane, tetrahydrofuran, dioxane; alcohols such as ethylalcohol. To the solution is added aryl boric acid derivative, e.g. phenyl boric acid, 3-methoxyphenyl boric acid, 4-ethoxycarbonylphenyl boric acid. Further, to the mixture are added a catalyst, e.g. palladium metal such as tetrakis (triphenylphosphine)palladium, in the presence of an inert gas, e.g. argon gas. The mixture is stirred at about 10°C to 100°C for a few minutes to several hours. After removing the insolubles, the

25


30

35

desired compound (Ia) is obtained.

The foregoing production method is shown in Scheme 6. In Scheme 6, X'' denotes halogen, R³¹ denotes an optionally substituted C₆₋₁₄ aryl, and other groups have the same meanings defined as above.

Scheme 6:



15

Production Method 7:

Production of a derivative which has 2,5-dioxo-4-imidazolidinyl at 5-position is illustrated in Scheme 7, infra:

20

The formyl derivative (xv), which is obtained in the above Production Method 3 or its similar method, is reacted with a sodium bisulfite in an appropriate solvent, e.g. water, ethanol. The reaction is carried out at 0°C to 80°C under stirring to give a sulfuric acid additive (xxii).

25


To the additive (xxii) is added a cyano compound, e.g. potassium cyanide, sodium cyanide, in an appropriate solvent, e.g. aqueous ethanol, aqueous tetrahydrofuran, dioxane, in the presence of an equivalent to an excess amount of a base, e.g. ammonium carbonate. The reaction is carried out at 0°C to 80°C under stirring, and under refluxing when required, to give an imidazoldiinyll derivative (Ib).

30

The foregoing method is shown in Scheme 7. In Scheme 7, all the groups have the same meaning as defined above.

35

Scheme 7:



Production Method 8:


Production of a compound which has an oxazoly group at 5-position is illustrated in Scheme 8, infra:

20 The derivative (xv), which has a formyl group at 5-position, is reacted with an equivalent to excess amount of tosylmethylisoniazide in an appropriate solvent, e.g. methanol, ethanol, in the presence of an equivalent to an excess amount of a base, e.g.

25 potassium carbonate. The reaction is carried out at 0°C to 80°C under stirring, and under refluxing when required, to give a derivative (Ic) which has an oxazoly group at 5-position.

30 The foregoing production method is shown in Scheme 8. In scheme 8, other groups have the same meaning as defined above.

Scheme 8:



10 Production Method 9:

Production of a compound having 4-imidazolyl group or 4-thiazolyl group at 5-position is illustrated in Scheme 9, infra:

15 4,7-Dihydro-5-acyl-4-oxothieno[2,3-b]pyridine derivative (xxiv), obtained in said Production Method 4 or 5, is dissolved in an appropriate solvent, e.g. acetic acid, methanol, tetrahydrofuran, ethylether, dioxane.

20 To the solution an equivalent to a small excess of halogenating agent, e.g. bromine or iodine, is added dropwise under a room temperature or ice-cooling. The mixture is stirred at a temperature of 0°C to 80°C to give an α -haloketon derivative (xxv).

25 Said α -haloketon derivative (xxv) is dissolved in an appropriate solvent, e.g. methanol, tetrahydrofuran, ethylether, dioxane, dimethylformamide. To the solution is added an equivalent to a small excess amount of amidine derivative under room temperature or ice-cooling. The mixture is stirred at a temperature of 0°C to 80°C, and the system is heated if required, to give a 4-imidazolyl derivative (Id).


30 The α -haloketone derivative (xxv) is reacted with a thiocarbamoyl derivative in an appropriate solvent, e.g. methanol, ethanol, dimethylformamide, dimethylacetamide, at a temperature of about 10°C to 35 100°C under stirring to give a 4-thiazolyl derivative

(Ie).

Similar to the above, the α -haloketone derivative is reacted with a thioglycolic acid amide, and then subjected to a ring-closure reaction to give a 1,4-thiazinyl derivative.

The foregoing method of the production of imidazolyl derivative and thiazolyl derivative is shown in Scheme 9. In Scheme 9, R^{43} denotes hydrogen atom, C_{1-6} alkyl or C_{6-14} aryl. R^{44} denotes hydrogen atom, C_{1-6} alkyl or C_{6-14} aryl. R^1 , R^2 , R^3 , R^5 and n have the same meaning as defined above.

Scheme 9:



Production Method 10:


Production of a compound having 2-oxazolyl group at 5-position is illustrated in Scheme 10, infra:

4,7-Dihydro-5-carbamoyl-4-oxothieno[2,3-6]pyridine derivative (xvi), obtained by the first step in the above Production Method 5, is dissolved in an appropriate solvent, e.g. methanol, ethanol, tetrahydrofuran, dioxane, and to the solution is added an equivalent to a small excess of α -haloketone compound dropwise under room temperature or ice-

cooling. The mixture is stirred at 0°C to 80°C, and refluxed under heating if required, to give a 2-oxazolyl derivative (If).

The foregoing method is shown in Scheme 10. In Scheme 10, R⁴⁵ denotes hydrogen atom, C₁₋₆ alkyl or C₆₋₁₄ aryl. Xa denotes a halogen atom and R¹, R², R³, R⁵ and n have the same meaning as defined above.

Scheme 10:



15 Production Method 11:

Production of a compound having 2-thiazolyl at 5-position is illustrated in Scheme 11, infra:


To a solution of 4,7-Dihydro-5-carbamoyl-4-oxothieno[2,3-b]pyridine derivative (xxvi) in an appropriate solvent, e.g. toluene, tetrahydrofuran, dioxane, an equivalent amount or a small excess amount of thioamide reagent, e.g. Lawessons reagent, is added under room temperature or ice-cooling. The mixture is stirred at a temperature of 0°C to 80°C, and subjected to refluxing under heating if required, to give a 4,7-dihydro-5-thiocarbamoyl-4-oxothieno[2,3-b]pyridine derivative (xxvii).

Said thicarbamoyl derivative (xxviii) is dissolved in an appropriate solvent, e.g. methanol, ethanol, tetrahydrofuran, dioxane, and to the solution is added dropwise an equivalent amount to a small excess amount of α -haloketone compound under room temperature or ice-cooling. The mixture is stirred at a temperature of about 0°C to 80°C, and is subjected to refluxing under heating, to give 2-thiazolyl derivative (Ig).

The foregoing method is shown in Scheme 11. In

Scheme 11, R^{46} denotes hydrogen C_{1-6} alkyl or C_{6-14} aryl. Xa denotes a halogen atom. R^1 , R^2 , R^3 , R^5 and n have the same meaning as defined above.

Scheme 11:



Production Method 12:

20 Production of a compound having 3-pyrazolyl group at 5-position is illustrated in Scheme 12, infra:

25 To a solution of 4,7-dihydro-5-acetyl-4-oxothieno[2,3-b]pyrimidine (xxviii), obtained by the method of Production Method 5, in an appropriate solvent, e.g. methanol, ethanol, tetrahydrofuran, dioxane is added dropwise an excess amount of formyl ethyl ester and a base, e.g. sodium ethoxide, under room temperature or under ice-cooling. The mixture is stirred at a temperature of 0°C to 80°C to give an α -formylketone derivative (xxx).


30 The α -formylketone derivative (xxx) is dissolved in an appropriate solvent, e.g. water, methanol, tetrahydrofuran, dioxane, dimethylformamide. To the solution is added an equivalent to a small excess of hydrazine derivative or its salt under room temperature or ice-cooling. The mixture is stirred at a

35

temperature of about 0°C to 80°C, and subjected to refluxing under heating if required, to give a 3-pyrazolyl derivative (Ih).

The foregoing method is shown in Scheme 12. In Scheme 12, R¹, R², R³, R⁵ and n have the same meaning as defined above.

Scheme 12:



Production Method 13:

Production of a compound having 2-triazolyl at 5-position is illustrated in Scheme 13, infra:

25 4,7-Dihydro-5-thiocarbamoyl-4-oxothieno[2,3-b]pyrimidine derivative (xxxi), which is produced in the first process of Production Method 11, is dissolved in an appropriate solvent, e.g. ethyl ether, dimethylformamide, tetrahydrofurane, dioxane, dichloromethane. To the solution is added an equivalent amount to a small excess amount of methyl iodide at a temperature of 0°C to 80°C, and the mixture is subjected to refluxing under heating if required, to give a derivative of tetra salt.


35 To a solution of the derivative in an appropriate solvent, e.g. dimethylformamide, or to the derivative

without such solvent, is added an excess amount of formic acid hydrazide under room temperature or ice-cooling.

The mixture is stirred at room temperature to 200°C, to give a 2-triazol derivative (Ii).

The foregoing method is shown in Scheme 13. In Scheme 13, the groups have the same meaning as defined above.

Scheme 13:



Production Method 14:

25 Production of a compound having 2-oxazolinyl at 5-position illustrated in Scheme 14, infra:


2,7-Dihydro-4-oxothieno[2,3-b]pyridine-5-carboxylic acid ester (xxxviii) is added dropwise under ice-cooling to an excess amount of a solution of aluminum amide of ethanol amine in dichloromethane. The mixture is stirred for one to 4 hours at room temperature to produce an amide derivative.

To the solution of the amide derivative in an appropriate solvent, e.g. dichloromethane, ethyl ether, tetrahydrofuran, is added thionyl chloride under ice-cooling.

The mixture is stirred at a temperature of 0°C to room temperature to give a 2-oxazolinyl derivative (Ij).

The foregoing method is shown in Scheme 14. In the Scheme 14, R¹, R², R³, R⁵ and n have the same meaning as defined above.

Scheme 18:



Production Method 15:

Production of the compound (I) wherein R⁴ is a group bonded through a nitrogen atom is illustrated in Scheme 15, infra:

The compound (xxxv), which can be produced by a similar manner of Production Methods 4 or 5, is dissolved in an appropriate solvent, e.g. pyridine. To the solution is added an equivalent to a small excess amount of hydroxylamine derivative or its salt, and the mixture is reacted under room temperature or an elevated temperature, to produce oxime derivative (xxxvi). The oxime derivative (xxxvi) is dissolved in an appropriate solvent, e.g. pyridine, and to the solution is added an equivalent to a small excess amount of an acylating agent, e.g. acid halide, acid


anhydride, sulfonic acid halide.

The mixture is reacted, under room temperature or under heating for 1 to 12 hours to give a dislocation form (Ik).

5 The dislocation form (Ik) is dissolved in an appropriate solvent, e.g. ethylalcohol, and to the solution is added an alkali, e.g. an sodium hydroxide solution, and the mixture is stirred for about 2 hours to cause an alkali hydrolysis reaction, whereby a
10 primary amino derivative (Im) is produced.

The foregoing method is shown in Scheme 15. In Scheme 15, R^1 , R^2 , R^3 , R^5 and n have the same meaning as defined above. Ac means acetyl group.

Scheme 15:



From thus obtained primary amino derivative (Im), various derivatives can be produced by alkylation, acylation, sulfonation, imidation and so forth.

Production Method 16:

35 Production of the compound (I) wherein R^4 is a group bonded through an oxygen atom is illustrated in

Scheme 16, infra:

The compound (xxxvii), which can be obtained by the method described in Production Methods 4 or 5, is dissolved in an appropriate solvent, e.g.

5 dichloromethane. To the solution is added a small excess amount, e.g. 1.2 to 1.5 equivalent, of peracids, e.g. chlorobenzoic acid, and the mixture is stirred for 1 to 6 hours to give a dislocation from (In).


10 The dislocation form (In) is subjected to a reaction by stirring the mixture of the dislocation form (In) with an alkali, e.g. 2N sodium hydroxide solution, in an appropriate solvent, e.g. tetrahydrofuran, under room temperature or under heating, e.g. 40 to 60°C, for 1 to 12 hours, to give an
15 alcoholic derivative (Io).

The alcoholic derivative (Io) is dissolved in an appropriate solvent, e.g. dimethylformamide, and to the solution are added an alkali, e.g. potassium carbonate, and alkyl halide, e.g. isopropyl bromide, and the
20 mixture is stirred for about one to 24 hours at room temperature to heating, e.g. 40 to 80°C, to give alkoxy derivative (Ip).

Furthermore, when the alkoxy group is isopropoxy group, the alkoxy derivative (xviii) is dissolved in an
25 appropriate solvent, e.g. dichloromethane, an excess amount of Lewis acid, e.g. borane trichloride, is added to the solution and the mixture is stirred for one to 6 hours under ice-cooling or room temperature, to give de-alkylated alcoholic derivative (Io).

30 The foregoing methods are shown in Scheme 16. In Scheme 16, R^1 , R^2 , R^3 , R^5 and n have the same meaning as defined above. R^{30} and $R^{4'}$ denote an alkyl group. X_a denotes a halogen atom.

Scheme 16:



From the obtained alcoholic derivative (xvii), various derivatives can be produced by alkylation, acylation, alkenylation, sulfonation and so forth. Production Method 17

Production of the compound (I) wherein R^4 is a group bonded through a sulfur atom is illustrated in Scheme 17, infra:

At first, thioglycolic acid ester is reacted with an alkali iodide, and then the product is reacted with dimethylaminomethylene compound to give a compound (xxviii).

The 2-aminothiophen derivative (xxix), which is obtained in the above Production Method 1, Scheme 1, is dissolved in an appropriate solvent, e.g. ethyl alcohol, and to the solution is added a base, e.g. an aqueous sodium hydroxide solution, to cause to alkali hydrolysis to give a compound (xxxx).

The compound (xxxx) is reacted with the compound (xxviii) shown above by stirring in an appropriate

solvent, or without any solvent, under heating, e.g. 80 to 150°C, for 1 to 6 hours to give an amino substituted derivative (xxxxi).


5 The derivative (xxxxi) is heated, e.g. at 150 to 250°C, in an appropriate solvent, e.g. diphenyl ether, for 30 minutes to 3 hours to give a cyclic form (xxxxii).

10 The cyclic form (xxxxii) is reacted with a compound of the formula: $Xa-(CH_2)_n-R^3$ by a similar manner as described above in the reaction with a compound of the formula: $Xa-(CH_2)_n-R^3$ in the Production Method 6, to give a compound (Iq).

15 Furthermore, the compound (Iq) is reacted by stirring with an equivalent to an excess amount of peracid compound, e.g. m-chlorobenzoic acid, in an appropriate solvent, e.g. dichloromethane, under ice-cooling for 5 minutes to about 2 hours to give sulfoxide derivative (Ir).

20 The foregoing methods are shown in Scheme 17. In Scheme 17. R^1 , R^2 , R^3 and n have the same meaning as defined above. $R^{4''}$ denotes an alkyl group.

Scheme 17:



Production Method 18:

30 Production of the Compound wherein it has a phenyl group substituted by an alkenyl group which may optionally be substituted at 2-position is illustrated in Scheme 18, infra:


35 4,7-Dihydro-2-(4-aminophenyl)-4-oxothieno[2,3-b]pyrimidine derivative (Is) is reacted with diazonizing agent, e.g. sodium nitrite, isoamyl nitrite, in an appropriate proper solvent, e.g. dimethylformamide, dichloromethane, tetrahydrofuran,

dioxane, acetonitrile, water, etc, to give a diazonium salt.


To the diazonium salt is added one equivalent to excess amount of an alkenyl derivative, e.g. olephine compound, and palladium catalyst, e.g. bis(dibenzylideneacetone)palladium. The reaction is conducted at 0°C to 80°C under stirring, to give the desired product, i.e. the compound (It).

The foregoing production method is shown in Scheme 18. In Scheme 18, R^{32} and R^{33} independently are an acyl group, R^{34} denotes a hydrogen atom or C_{1-6} alkyl. Other groups have the same meaning as defined above.

Scheme 18:



(Is)



(It)



Production Method 19:

Production of a compound which has an aminophenyl group substituted by (1) an optionally substituted alkyl group or (2) an optionally substituted homocyclic group is illustrated in Scheme 19, infra:

4,7-Dihydro-2-(4-aminophenyl)-4-oxothieno[2,3-

b]pyrimidine derivative (Iu) is dissolved in an appropriate solvent, e.g. acetic acid, dimethylformamide, dichloromethane, tetrahydrofuran, dioxane. To the solution is added one equivalent to excess amount of Michael acceptor derivative, e.g. acrylic acid ester, or an oxirane derivative, e.g. epoxy compound. The reaction is carried out at 0°C to 80°C under stirring to give the desired compound (Iv).

The foregoing production method is shown in Scheme 19. In Scheme 19, R³⁵ to R³⁹ denote alkyl group -R⁴⁰ denotes a group -C(R³⁶)-CO-R³⁵ or a group -C(OH)R³⁶R³⁹. Other groups have the same meaning as defined above. Scheme 19:



Production Method 20:

Production of a compound which has an aminophenyl group substituted by (1) an optionally substituted alkyl or (2) an optionally substituted homo-cyclic group is illustrated in Scheme 20, infra:

4,7-Dihydro-2-(4-aminophenyl)-4-oxothieno[2,3-b]pyrimidine derivative (Iw) is dissolved in an


appropriate solvent, e.g. pyridine, dimethylformamide, dichloromethane, tetrahydrofuran, ethylether, dioxane. To the solution is added one equivalent to one excess amount of acid chloride or acid anhydride, e.g.
5 trifluoroacetic acid anhydride. The reaction is carried out at 0°C to 80°C under stirring to give a derivative (Ix).

The obtained derivative (Ix) is dissolved in a solvent, e.g. pyridine, dimethylformamide,
10 dichloromethane, tetrahydrofuran, ethylether, dioxane, acetone, and to the solution is added one equivalent to an excess amount of a base, e.g. potassium carbonate, triethylamine, sodium hydrogen, and one equivalent to one excess amount of a halogenated alkyl, e.g. methyl
15 iodide, propyl iodide, benzyl iodide. The reaction is carried out at 0°C to 80°C under stirring.

The obtained derivative is subjected to alkali hydrolysis using small excess amount of 1N sodium hydroxide in an appropriate solvent, e.g.
20 tetrahydrofuran, dioxane, ethanol, methanol, acetone, to give the desired derivative (Iy).

The foregoing method is shown in Scheme 20. In Scheme 20, the group R⁴¹ represents C₁₋₆ alkyl or trifluoromethyl. The group R⁴² is an optionally
25 substituted alkyl group or an optionally substituted homo-cyclic group. Other groups have the same meaning as defined above.

Scheme 20:



Production Method 21: Exchange the group at 3-position:

The group at 3-position of the compound can be exchanged by the following method as illustrated in Scheme 21.

20 The compound (Iz) is stirred together with N-bromosuccinimide (NBS) in an appropriate solvent, e.g. halogenated hydrocarbons such as carbon tetrachloride and chloroform, in the presence of α, α' -azobisisobutyronitrile (AIBN), at temperatures ranging from about 30 to 100°C to give a compound (II'), and if
 25 required the compound (II') is subjected to a reaction with aliphatic carboxylic acid, alkylsulfonic acid, or alkylarylsulfonic acid to cause a reaction of exchanging the group at 3-position.

30 The compound (II') is reacted with an equivalent mole to a small excess amount (about 3 mole) of primary or secondary amine, e.g. $R^{1'}-H$ to give a compound (III'). The reaction can be carried out in an appropriate solvent which does not adversely effect the
 35 reaction. As the solvent, mention is made of amides such as dimethylformamide or dimethylacetamide,

nitrites such as acetonitrile, alcohols such as ethanol, and furthermore diethoxyethane, tetrahydrofuran, dioxane, toluene, dichloromethane, chloroform, ethylether, acetone and ethyl acetate can be used. In this reaction, if necessary, a base may be used. As the base, mention is made of a tertiary organic amine, e.g. trimethylamine, triethylamine, diisopropylamine, pyridine, 1,8-diazabicyclo[5,4,0]-7-undecene (DBU), and an inorganic salt, e.g. anhydrous potassium carbonate. The reaction is carried out at a temperature of about 10 to 100°C. The reaction time is about 0.5 to 8 hours. When the reaction is carried out under stirring, the reaction proceeds smoothly.


This reaction gives the compound (III'). The production method 3 described above is shown in Scheme 21 below:

In Scheme 21, the groups $R^{1''}$, $R^{1'}$, R^2 , R^3 , R^5 and m have the same meaning as defined above. m denotes an integer of 0 to 6. X denotes a leaving group.


As the leaving group shown by X , mention is made of, for example, a group which is potentially substituted by a nucleophilic reagent such as a hydrocarbon residue having a hetero atom, e.g. an oxygen atom, a sulfur atom, a nitrogen atom, being negatively charged. The preferable examples of the leaving group include halogen, e.g. iodine, bromine, chlorine), alkanoyloxy, e.g. acetoxy), alkylsulfonyloxy, e.g. methanesulfonyloxy), alkyl-arylsulfonyloxy (e.g. p-toluenesulfonyloxy).

Scheme 21:

55



10



20 The compound having a group R^4 at 5-position can be produced by the similar manner as above.

22. Other methods:

25 The substituents on the compound (I) can be converted to other substituents by per se known and conventional methods. Examples of the methods are shown below.

30 (i) The nitro group as the substituent can be converted to an amino group when the starting compound is dissolved in an appropriate solvent, e.g. ethanol, methanol, and (a) to the solution is added palladium-carbon, and the mixture is reacted at room temperature for one to 12 hours under hydrogen atmosphere, or (b) to the solution is added iron powder and hydrochloric acid, and the mixture is reacted at room temperature for one to 12 hours.

35 (ii) The amino group can be converted to an acylated

amino group by dissolving the starting compound in an appropriate solvent, e.g. tetrahydrofuran, dimethylsulfoxide, to the solution is added potassium carbonate, pyridine and triethylamine as a base and
5 acid anhydride or acid halide. The mixture is reacted at a room temperature for one to 10 hours under stirring.

(iii) From an amino compound, a compound having an amino group is converted to alkenyl-amino compound.
10 For example, the starting compound is dissolved in an appropriate solvent, e.g. acetic acid, dimethylformamide, dichloromethane, tetrahydrofuran, dioxane, acetonitrile, to the solution is added diazonizing agent, e.g. sodium nitrite, isoamyl
15 nitrite, to the mixture is added palladium catalyst, e.g. bis(dibenzylideneacetone)palladium and one to excess equivalents of alkenyl derivative, and the mixture is stirred at room temperature to heating (about 80°C) for one to 12 hours.

20 (iv) A carbon atom can be introduced to the amino group, for example, to the starting compound in an appropriate solvent, e.g. acetic acid, dimethylformamide, dichloromethane, tetrahydrofuran, dioxane, is added an acrylic acid derivative or oxirane
25 derivative, e.g. epoxide compound. The mixture is stirred at 0 to 80°C for 6 to 24 hours.

(v) A sulfur atom can be introduced to the amino group in the compound, for example, to the starting compound in an appropriate solvent, e.g. pyridine,
30 dimethylformamide, dichloromethane, tetrahydrofuran, ethylether, dioxane, is added halide of sulfur compound. The mixture is stirred at 0 to 80°C for 6 to 24 hours.

(vi) The substituent, formyl group, can be converted to
35 methyl group by dissolving a starting compound in an appropriate solvent, e.g. tetrahydrofuran, and to the

mixture is added an organic borane, derivative, e.g. dimethylsulfide borane, and the mixture is reacted at room temperature to heating under reflux for a several hours, e.g. one to 3 hours.

- 5 (vii) From methoxy derivative, actonyloxy derivative can be prepared by dissolving the starting material in an appropriate solvent, e.g. dichloromethane, and to the solution is added one to excess equivalents of Lewis acid, e.g. aluminium chloride, and thiol compound
10 or sulfide compound, e.g. dimethylsulfide, and the mixture is reacted at ice-cooling to room temperature for one to 10 hours, and then the obtained hydroxy derivative is dissolved in an appropriate solvent, e.g. dimethylformamide, to the solution is added a base,
15 e.g. sodium hydroxide or potassium carbonate, and an alkyl halide. The mixture is reacted at a room temperature for one to 12 hours.

- (viii) A methoxy group can be changed to isopropoxy by dissolving the starting material in an appropriate
20 solvent, e.g. dichloromethane, to the solution is added one to excess equivalents of Lewis acid, e.g. aluminum chloride, and thiol compound or sulfide compound, e.g. dimethylsulfide, and the mixture is reacted at room temperature to ice-cooling for one to 10 hours.

- 25 (ix) An aminocarbonyl group can be introduced by dissolving a starting compound having halogen atom in an appropriate solvent, e.g. dimethoxyethane, to the solution is added arylborric acid derivative, a base, e.g. sodium carbonate, a palladium compound e.g.
30 tetrakis(triphenylphosphine)palladium(0), as a catalyst and the mixture is refluxed 1 to 6 hours.

- (x) An alkylthio compound can be converted to an alkylsulfinyl compound or an alkylsulfonyl compound by reacting a starting compound with an oxidizing agent,
35 e.g. metachloroperbenzoic acid, in an appropriate solvent, e.g. dichloromethane, at ice-cooling to

heating. With vigorous heating or by treating with an excess amount of oxidizing agent, an alkylsulfonyl compound is obtained.

As salts of the compound (I) of this invention
5 obtained thus above, physiologically acceptable acid addition salts are preferable. Examples of such salts include those with an inorganic acid, e.g. hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid and phosphoric acid, or those with an organic acid, e.g.
10 formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid. Further, when the compound (I) of this invention has an
15 acid group such as -COOH, the compound(I) may form a salt with an inorganic base, e.g. an alkali metal or alkaline earth metal such as sodium, potassium, calcium and magnesium; ammonia, or an organic base, e.g. trimethylamine, triethylamine, pyridine, picolin,
20 ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine and N,N'-dibenzylethylenediamine.

The compounds or salts thereof of the present invention produced thus above can be isolated and purified by conventional separating means such as
25 recrystallization, distillation and chromatography. In the case where the compound (I) is produced in the free form, it can be converted to a salt thereof by a per se conventional means or a method analogous thereto. On the contrary, when it is obtained in the form of a
30 salt, it can be converted to its free form or to any other salt.

In the case where the compound or a salt thereof of the present invention is an optically active compound, it can be separated into d-compound and l-
35 compound by means of a conventional optical resolution.

Since the compounds (I) of this invention or its

salt, hereinafter it is sometimes abbreviates as "the present compound", have a GnRH antagonistic activity and are low in toxicity, and is stably absorbed through oral administration and shows GnRH antagonistic activity over a long time, they can be safely used for the therapy of male hormone or female hormone dependent diseases as well as the therapy of diseases caused by excess secretion of these hormones, in mammals, e.g. human, monkey, cow, horse, dog, cat, rabbit, rat and mouse, suppressing the secretion of gonadotropic hormone by the action of GnRH receptor antagonistic action. More specifically, the present compound are effective as a prophylactic or therapeutic agent for the prevention or treatment of several hormone dependent diseases, for example, a sex hormone dependent cancer, e.g. prostate cancer, cancer of the uterine cervix, breast cancer, pituitary adenoma, benign prostatic hypertrophy, myoma of the uterus, endometriosis, precocious puberty, amenorrhea, premenstrual syndrome, polycystic ovary syndrome and acne vulgaris. And, the present compound are also effective as a fertility controlling agent in both sexes, e.g. pregnancy controlling agents and menstrual cycle controlling agents. The present compound can be further used as a contraceptive of male or female and, as an ovulation-inducing agent of female. The present compound can be used as an infertility treating agent by using a rebound effect owing to a stoppage of administration thereof. Further, the present compounds are useful as modulating estrous cycles in animals in the field of animal husbandry, and as an agent for improving the quality of edible meat or promoting the growth of animals. The present compounds are also useful as an agent for spawning promoting in fish. While the present compound can be used singly, they can also effectively be used by administering in

combination with a steroidal or non-steroidal antiandrogenic agent. The present compound can be used for the suppressing a passing ascent of testosterone concentration in plasma, the ascent which occurs in administration of GnRH super antagonist such as leuprorelin acetate. The present compound can effectively be used by administering in combination with a chemotherapeutic agent for cancer. In treatment of prostate cancer, examples of the chemotherapeutic agent include Ifosfamide, UFT, Adriamycin, Peplomycin, Cisplatin and the like. In treatment of breast cancer, examples of the chemotherapeutic agent include Cyclophosphamide, 5-FU-, UFT, Methotrexate, Adriamycin, Mitomycin C, Mitoxantrone and the like.

When the present compound is employed, in the field of animal husbandry or fisheries, as prophylactic and therapeutic agents of the above-mentioned diseases, it can be administered orally or non-orally in accordance with per se known means. For example, it can be mixed with a pharmaceutically acceptable carrier and administered orally as a solid preparation such as tablet, capsule, granule or powder, or non-orally as intravenous, subcutaneous or intramuscular injection, or as suppository or a sublingually administrable tablet. Further, it can be sublingually, subcutaneously or intramuscularly administered as a prolonged release formulation such as sublingually administrable tablets, or microcapsules. The dosage can vary with, e.g. the degree of affliction, age, sex, body weight and difference of sensitivity of the subject to be administered; the time and intervals of administration, treated dosage forms and kinds of the medicinal preparation; and kinds of the effective components, and it ranges usually, though not specifically limited to, from about 0.1 to 30 mg, preferably from about 0.1 to 3 mg, more preferably from

about 0.1 to 1 mg, relative to 1 kg body weight of mammals, which is administered usually once daily or by 2 to 4 divided dosages. The daily dose when used in the field of animal husbandry or fishery varies with the conditions analogous to those mentioned above, it ranges, relative to 1 kg body weight of the subject animal or fish, from about 0.01 to 5 mg, preferably from about 0.03 to 3 mg, once daily or by 2 to 3 divided dosages.

As the above-mentioned pharmaceutically acceptable carriers, conventional various organic or inorganic carriers are used, and they can be incorporated as excipients, lubricants, binders, disintegrants in solid compositions; and as solvents, solubilisers, suspending agents, isotonizing agents, buffering agents and pain-easing agents in liquid and solid compositions. And, depending on necessity, further additives such as preservatives, anti-oxidants, coloring agents and sweeteners can also be used.

Preferable examples of the above-mentioned excipients include lactose, sugar, D-mannito, starch, crystalline cellulose and more volatile silicon dioxide. Preferable examples of the above-mentioned lubricants include magnesium stearate, calcium stearate, talc and colloid silica. Preferable examples of the above-mentioned binders include crystalline cellulose, sugar, D-mannitol, dextrin, hydroxypropyl cellulose, hydroxymethyl cellulose and polyvinyl pyrrolidone. Preferable examples of the above-mentioned disintegrants include starch, carboxymethyl cellulose, carboxymethyl cellulose calcium, cross carmelose sodium, cross carmelose sodium and carboxymethyl starch sodium. Preferable examples of the above-mentioned solvents include water for injection, alcohol, propylene glycol, macrogol, sesame oil and corn oil. Preferable examples of the above-

mentioned solubilizers include polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, tris-aminomethane, cholesterol, triethanolamine, sodium carbonate and sodium citrate. Preferable examples of the above-mentioned suspending agents include surfactants such as stearyl triethanolamine, sodium lauryl sulfate, lauryl aminopropionic acid, lecithin, benzalkonium chloride, benzetonium chloride and monostearic glyceryl ester; and hydrophilic polymers such as polyvinyl alcohol, polyvinyl pyrrolidone, sodium carboxymethyl cellulose, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose and hydroxypropyl cellulose. Preferable examples of the above-mentioned isotonizing agents include sodium chloride, glycerin and D-mannitol. Preferable examples of the above-mentioned buffering agents include buffer solutions such as phosphate, acetate, carbonate and citrate. Preferable examples of the above-mentioned pain-easing agents include benzyl alcohol. Preferable examples of the above-mentioned preservatives include para-hydroxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid and sorbic acid. Preferable examples of the above-mentioned anti-oxidants include sulfite and ascorbic acid.

To the compound of this invention, are added, for example, a suspending agent, a solubilizer, a stabilizer, an isotonizing agent and a preservative, then the mixture is formulated, in accordance with a per se known method, into an intravenous, subcutaneous or intramuscular injection. These injections can be processed into lyophilized preparations, when necessary, by a per se known method.

Examples of the above-mentioned pharmaceutical composition are oral agents (e.g. diluted powders, granules, capsules and tablets), injections, dropping

injections, external agents (e.g. transnasal preparations, percutaneous preparations, etc.), ointments (e.g. rectal ointment, vaginal ointment, etc.) and the like.

5 Such pharmaceutical compositions can be manufactured by a per se known method commonly used in preparing pharmaceutical compositions.

10 The compound of the present invention or a salt thereof can be made into injections either in a form of an aqueous injection together with dispersing agents, e.g. Tween 80 (Atlas Powder, U.S.A.), HCO 80 (Nikko Chemicals, Japan), polyethylene glycol, carboxymethylcellulose, sodium alginate, etc.,
15 preservatives, e.g. methyl paraben, propyl paraben, benzyl alcohol, etc., isotonizing agents, e.g. sodium chloride, mannitol, sorbitol, glucose, etc., and the like or in a form of an oily injection by dissolving, suspending or emulsifying in plant oil, e.g. olive oil, sesame oil, cotton seed oil, corn oil, etc., propylene
20 glycol and the like.

 In preparing a pharmaceutical composition for oral use, the compound of the present invention or a salt thereof is molded by compressing, for example, with fillers, e.g. lactose, sucrose, starch, etc.,
25 disintegrating agents, e.g. starch, calcium carbonate, etc., binders, e.g. starch, gum arabic, carboxymethylcellulose, polyvinylpyrrolidone, hydroxypropylcellulose, etc., or lubricants, e.g. talc, magnesium stearate, polyethylene glycol 6000, etc., and
30 the like. If necessary, the composition is coated by a per se known method with an object of masking the taste, as an enteric coating or for long-acting sustained release. Examples of coating agents therefore are hydroxypropylmethylcellulose,
35 ethylcellulose, hydroxymethylcellulose, hydroxypropylcellulose, polyoxyethylene glycol, Tween

80, pluronic F 68, cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, hydroxymethylcellulose acetate succinate, Eudragit (a copolymer of methacrylic acid with acrylic acid; manufactured by Rohm, Germany), red oxide of iron and the like. Subcoating layers may be provided between the enteric coating and the core according to per se known methods.

In preparing an external composition, the compound of the present invention or a salt thereof is subjected to a per se known method to give a solid, semisolid or liquid agent for external use. For example, the solid preparation is manufactured as follows. The compound of the present invention as it is or after adding/mixing fillers, e.g. glycol, mannitol, starch, microcrystalline cellulose, etc., thickeners, e.g. natural gums, cellulose derivatives, acrylic acid polymers, etc., and the like thereto/therewith is made into a powdery composition. With respect to the liquid composition, an oily or aqueous suspension is manufactured by the manner nearly the same as in the case of the injection. In the case of a semisolid composition, the preferred one is an aqueous or oily gel or an ointment. Each of them may be compounded with a pH adjusting agent, e.g. carbonic acid, phosphoric acid, citric acid, hydrochloric acid, sodium hydroxide, etc., an antiseptic agent, e.g. p-hydroxybenzoates, chlorobutanol, benzalkonium chloride, etc., and the like.

In the manufacture of an ointment for example, the compound of the present invention or a salt thereof can be made into an oily or an aqueous solid, semisolid or liquid ointment. Examples of the oily base material applicable in the above-mentioned composition are glycerides of higher fatty acids, e.g. cacao butter, Witepsols (manufactured by Dynamite-Nobel), etc.,

medium fatty acids, e.g. Miglyols (manufactured by Dynamite-Nobel), etc., and plant oil, e.g. sesame oil, soybean oil, cotton seed oil, etc., and the like. Examples of the aqueous base material are polyethylene glycols and propylene glycol and those of the base material for aqueous gel are natural gums, cellulose derivatives, vinyl polymers, acrylic acid polymers, etc.

By way of the following Reference Examples and Working Examples the present invention will be described more specifically, but they are not intended to limit the scope of this invention thereto.

¹H-NMR spectra were taken with the Varian GEMINI 200 (200 MHz) type spectrometer, JEOL LAMBDA300 (300MHz) type spectrometer or the Brucker AM 500 (500 MHz) type spectrometer, employing tetramethylsilane as the internal standard. All delta values were expressed in ppm.

The symbols used in the present specification have the following meanings:

s: singlet, d: doublet, t: triplet, dt: double triplet, m: multiplet, br: broad

Reference Example 1

Production of 2-amino-5-phenylthiophene-3-carboxylic acid ethyl ester:

To a mixture of ethyl cyanoacetate (6.1 g, 50 mmol), sulfur (1.61 g, 50 mmol), triethylamine (3.5 ml, 25 mmol) and dimethylformamide (10 ml) was added dropwise, with stirring at 45°C, phenylacetaldehyde (50% diethylphthalate solution; 12.05 g, 50 mmol) for 20 minutes. The mixture was stirred for 9 hours at 45°C, and the reaction mixture was concentrated. The resulting residue was extracted with ethylacetate. The extract was washed with an aqueous sodium chloride solution, which was then dried (MgSO₄), followed by

distilling off the solvent under reduced pressure. The residue was chromatographed on silica gel, followed by crystallization from ether-hexane to give slightly yellow plates (5.55 g, 45%), m.p. 124.5-125.5°C (value in literature reference 123-124°C).

Elemental Analysis for $C_{13}H_{13}NO_2S$:

	C(%)	H(%)	N(%)
Calcd.:	63.13	5.30	5.66
Found :	62.99	5.05	5.63

1H -NMR (200MHz, $CDCl_3$) δ : 1.37(3H, t, $J=7.1$ Hz), 4.30(2H, d, $J=7.1$ Hz), 5.97(2H, br), 7.17-7.46(6H, m). IR(KBr): 3448, 3320, 1667, 1590, 1549 cm^{-1} .

Reference Example 2

Production of 2-amino-4-methyl-5-(4-methoxyphenyl)thiophene-3-carboxylic acid ethyl ester:

A mixture of 4-methoxyphenylacetone (16.5 g, 0.10 mol), ethyl cyanoacetate (12.2 g, 0.10 mol), ammonium acetate (1.55 g, 20 mmol), acetic acid (4.6 ml, 80 mmol) and benzene (20 ml) was heated for 24 hours under reflux, while removing water produced in the reaction mixture using a Dean and Stark apparatus. After cooling, the reaction mixture was concentrated under reduced pressure. The residue was partitioned between dichloromethane and an aqueous sodium hydrogencarbonate solution. The organic layer was washed with an aqueous sodium chloride solution, which was then dried ($MgSO_4$), followed by distilling of the solvent under reduced pressure. To an ethanol (30 ml) solution of the residue were added sulfur (3.21 g, 0.10 mol) and diethylamine (10.4 ml, 0.10 mol). The mixture was stirred at 50-60°C for 2 hours and then concentrated, and the concentrate was extracted with ethyl acetate. The extract was washed with an aqueous sodium chloride solution and dried ($MgSO_4$), followed by distilling off the solvent under reduced pressure. The residue was chromatographed on silica gel, and crystallized from

ether-hexane to give a pale yellow plates (11.5 g, 40%), m.p. 79-80°C.

Elemental Analysis for $C_{15}H_{17}NO_3S$:

	C(%)	H(%)	N(%)	S(%)
5	Calcd.: 61.83 ;	5.88 ;	4.81 ;	11.01
	Found : 61.81 ;	5.75 ;	4.74 ;	10.82
	1H -NMR (200MHz, $CDCl_3$) δ : 1.37(3H,t,J=7.1Hz),			
	2.28(3H,s), 3.83(3H,s), 4.31(2H,q,J=7.1Hz),			
	6.05(2H,brs), 6.91(2H,d,J=8.8Hz), 7.27(2H,d,J=8.8Hz).			
10	IR(KBr): 3426, 3328, 1651, 1586, 1550, 1505, 1485 cm^{-1} .			
	FAB-MS m/z: 291 (M^+)			

Reference Example 3

Production of 2-amino-4-methyl-5-phenylthiophene-3-carboxylic acid ethyl ester:

15 In a similar manner as described in Reference Example 2, phenylacetone was employed instead of 4-methoxyphenylacetone. Also employing cyanoacetic acid ethyl ester (10.5 g, 86.5 mmol), ammonium acetate (1.34 g, 17 mmol), acetic acid (3.96 ml, 69.2 mmol), sulfur
20 (2.78 g, 86.5 mmol) and diethylamine (8.95 ml, 86.5 mmol), and recrystallizing from ether-hexane colorless needles (9.05 g, 40%) was obtained, m.p. 64-65°C. Value is literature reference: 95°C.

Elemental Analysis for $C_{14}H_{15}NO_2S$:

	C(%)	H(%)	N(%)
25	Calcd.: 64.34 ;	5.79 ;	5.36
	Found : 64.51 ;	5.77 ;	5.29
	1H -NMR (200MHz, $CDCl_3$) δ : 1.37(3H,t,J=7.1Hz),		
	2.33(3H,s), 4.32(2H,q,J=7.1Hz), 6.09(2H,br), 7.24-		
30	7.42(5H,m).		
	IR(KBr): 3388, 3278, 1665, 1584, 1549, 1481 cm^{-1} .		

Reference Example 4

Production of {3-Ethoxycarbonyl-5-(4-methoxyphenyl)-4-methylthiophen-2-yl}aminomethylene
35 malonic acid diethyl ester:

To the compound produced in Reference Example 2

(10 g, 343.3 mmol) was added diethyl ethoxymethylene malonate (7.45 g, 34.5 mmol). The mixture was stirred for 2 hours at 120°C. After cooling, to the reaction mixture was added ether to precipitate crystals. The crystals were collected by filtration and washed with ether once more, followed by drying over phosphorus pentoxide under reduced pressure to give pale yellow crystals (14.2 g, 90%), m.p.122-123°C.

¹H-NMR (200MHz, CDCl₃) δ: 1.32(3H,t,J=7.1Hz), 1.38(3H,t,J=7.2Hz), 1.41(3H,t,J=7.2Hz), 2.34(3H,s), 3.85(3H,s), 4.25(2H,q,J=7.1Hz), 4.38(2H,q,J=7.2Hz), 4.45(2H,q,J=7.2Hz), 6.95(2H,d,J=8.8Hz), 7.31(2H,d,J=8.8Hz), 8.22(1H,d,J=13.4Hz), 12.74(1H,d,J=13.1Hz).

IR(KBr): 2984, 1720, 1707, 1688, 1653, 1599, 1518, 1499 cm⁻¹.

Reference Example 5

Production of (3-ethoxycarbonyl-5-phenyl-4-methylthiophen-2-yl)aminomethylenemalonic acid ethyl ester:

In a similar manner as described in Reference Example 4, the objective compound was obtained. m.p.108-109°C

Reference Example 6

(1) Production of {3-carboxy-5-(4-methoxyphenyl)-4-methylthiophen-2-yl}aminomethylene malonic acid diethyl ester:

To a solution of the compound produced in Reference Example 4 (7.0 g, 15.2 mmol) in dioxane (20 ml) was added a solution of potassium hydroxide (5.0 g, 75.7 mmol) in ethanol (30 ml) at 60-70°C with stirring. The mixture was stirred for one hour at the same temperature range, and was allowed to stand for one hour at room temperature. To the reaction mixture was added 2N HCl (40 ml, 80 mmol) with ice-cooling. The reaction mixture was concentrated under reduced

pressure. Resulting yellow precipitate was collected by filtration, which was then washed with a mixture of cold water and ethanol, followed by drying over phosphorus pentoxide under reduced pressure to give yellow powder (6.1 g, 93%), m.p. 184-187°C.

¹H-NMR (200MHz, DMSO-d₆) δ: 1.24(3H,t,J=7.1Hz), 1.28(3H,t,J=7.2Hz), 2.30(3H,s), 3.80(3H,s), 4.15(2H,q,J=7.1Hz), 4.24(2H,q,J=7.2Hz), 7.03(2H,d,J=8.7Hz), 7.37(2H,d,J=8.7Hz), 8.08(1H,d,J=13.6Hz), 12.41(1H,d,J=13.6Hz).

IR(KBr): 3422, 2980, 1719, 1653, 1607, 1551, 1512 cm⁻¹.

(2) Production of (3-carboxy-5-phenyl-4-methylthiophen-2-yl)aminomethylanamalic acid ethyl ester:

Using the compound obtained in Reference Examples 5 in a similar manner as described in Reference Example 6(1), the objective compound was obtained. m.p.187-190°C.

Reference Example 7

(1) Production of 4-Hydroxy-2-(4-methoxyphenyl)-3-methylthieno[2,3-b]pyridine-5-carboxylic acid ethyl ester:

To polyphosphoric ester (PPE) (90 ml) was added the compound produced in Reference Example 5 (6.0 g, 13.8 mmol) in small portions at 190°C with stirring. The mixture was stirred for 30 minutes at the same temperature. The reaction mixture was poured into ice-water, and was subjected to extraction with ethylacetate. The extract solution was washed with an aqueous sodium chloride solution, which was then dried (MgSO₄), followed by distilling off the solvent under reduced pressure. The residue was chromatographed on silica gel to give yellow powders (3.65 g, 77%). As the sample for elemental analysis, the powder was recrystallized from ethanol to give yellow crystals, m.p.162-163°C.

Elemental Analysis for $C_{18}H_{17}NO_4S$:

	C(%)	H(%)	N(%)	S(%)
Calcd.:	62.96	4.99	4.08	9.34
Found :	62.89	5.04	4.01	9.34

5 1H -NMR (200MHz, $CDCl_3$) δ : 1.47(3H,t,J=7.1Hz),
2.63(3H,s), 4.87(3H,s), 4.49(2H,q,J=7.1Hz),
6.99(2H,d,J=8.8Hz), 7.44(2H,d,J=8.8Hz), 8.84(1H,s),
12.11(1H,s).

IR(KBr): 3434, 2992, 1692, 1601, 1582, 1535, 1504 cm^{-1} .

10 FAB-MS m/z: 344 (MH^+)

(2) Production of 4-hydroxy-2-phenyl-3-methylthieno[2,3-b]pyridine-5-carboxylic acid ethyl ester:

Using the compound obtained in Reference Example 6(2), the similar manner of Reference Example 7(1) gave the titled compound.

m.p. 155-157°C.

Reference Example 8

20 Production of 4-hydroxy-5-hydroxymethyl-2-(4-methoxyphenyl)-3-methylthieno[2,3-b]pyridine:

To a suspension (6 ml) of lithium aluminum hydride (0.0326 g, 0.87 mmol) in anhydrous tetrahydrofuran was added dropwise a solution of the compound produced in Reference Example 7 (0.20 g, 0.58 mmol) in anhydrous tetrahydrofuran (3 ml) at room temperature (15-35°C, the same range applies hereinafter). The mixture was then stirred for 30 minutes at room temperature, to which was added an aqueous solution of Rochelle salt. Resulting precipitate was removed by filtration. In this process, when necessary, the reaction mixture was subjected to heating under reflux to complete the reaction. The precipitate was washed with ethyl alcohol and chloroform, which was combined with the filtrate, followed by concentration under reduced pressure. The concentrate was partitioned between ethyl acetate and an aqueous sodium chloride solution.

The organic layer was dried (MgSO_4), from which the solvent was distilled off under reduced pressure to give white crystals (0.13 g, 74%).

mp > 300°C

5 ^1H -NMR (200MHz, DMSO-d_6) δ : 2.55(3H,s), 3.81(3H,s), 4.41(2H,s), 7.03(2H,d,J=8.8Hz), 7.40(2H,d,J=8.8Hz), 7.75(1H,s).

IR(KBr): 3210, 2930, 1613, 1506, 1255 cm^{-1} .

FAB-MS m/z: 302 (MH^+)

10 Reference Example 9

(1) Production of 4,7-dihydro-5-hydroxymethyl-7-(2-fluorobenzyl)-2-(4-methoxyphenyl)-3-methyl-4-oxothieno[2,3-b]pyridine:

To a solution of the compound produced in
15 Reference Example 8 (4.00 g, 13.3 mmol) in dimethylformamide (300 ml) were added, at room temperature, potassium carbonate (2.78 g, 20.0 mol), 2-fluorobenzyl chloride (2.89 g, 20.0 mol) and potassium iodide (1.10 g, 6.6 mmol). The mixture was stirred for
20 2 hours at room temperature. The reaction mixture was concentrated, and the concentrate was partitioned between dichloromethane and water. The aqueous layer was extracted with dichloromethane. The extract was washed with an aqueous sodium chloride solution, which
25 was then dried (MgSO_4), then the solvent was distilled off under reduced pressure. The residue was chromatographed on silica gel to give a pale yellow amorphous product, which was recrystallized from ethyl acetate to afford colorless crystals, m.p.159-160°C.

30 ^1H -NMR (200MHz, CDCl_3) δ : 2.67(3H,s), 3.85(3H,s), 4.59(2H,s), 5.19(2H,s), 6.96(2H,d), 7.1-7.2(3H,m), 7.3-7.5(3H,m), 7.47(1H,s).

(2) Production of 4,7-dihydro-2-phenyl-3-methyl-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine-5-carboxylic acid ethyl ester:
35

Using the compound obtained in Reference Example

7(2), the similar procedure gave the titled compoune.
m.p.184-186°C.

Reference Example 10

5 Production of 4,7-dihydro-2-(4-methoxyphenyl)-3-methyl-5-formyl-7-(2-fluorobenzyl)-4-oxothieno[2,3-b]pyridine:

To a solution of the compound (4.10 g) obtained in Reference Example 9(1) in chloroform is added manganese dioxide (20.5 g). The mixture was stirred for one hour
10 under room temperature.

After Celite filtration, the filtrate was concentrated under reduced pressure, the obtained residue was purified with silica gel column chromatography, and recrystallized from methylene
15 chloride-ethyl acetate to give colorless crystals (3.72 g, Yield 83%).

¹H-NMR (200MHz, CDCl₃) δ: 2.66(3H,s), 3.85(3H,s), 5.26(2H,s), 6.96(2H,d), 7.1-7.4(6H,m), 8.17(1H,s), 10.44(1H,s).

20 Reference Example 11

Production of methyl 2-isopropylthioacetate:

To a solution of thioglycolic acid methyl ester (75 g, 707 mmol) in methanol (500 ml) was added potassium carbonate (107.4 mg, 777 mmol) and isopropyl
25 iodide (150 g, 882 mmol) under ice-cooling. The mixture was put back to room temperature and stirred for two days, and for one hour at 60°C. The reaction mixture was partitioned between ether (800 ml) and water. The aqueous layer was extracted with ether (200
30 ml), and the extracts were combined and washed with an aqueous sodium chloride solution, dried with Na₂SO₄, and the solvent was removed off. The resultant oily product (105 g, 100%) was used for the next reaction step without purification.

35 ¹H-NMR (CDCl₃) δ: 1.26(6H,d,J=6.6Hz), 3.01-3.09(1H,m), 3.25(2H,s), 3.72(3H,s).

Reference Example 12

Production of methyl 2-(N,N-dimethylaminomethylene)-2-isopropylthioacetate:

5 The compound (105 g, 707 mmol), obtained in Reference Example 11, and N,N-dimethylformamidedimethylacetal (150 g, 1,260 mmol) were dissolved in benzene (500 ml). The mixture was refluxed under heating for 5 hours, while removing water which occurs in the reaction system. Thus
10 obtained reaction mixture was purified by distillation to give an oily product (19 g, 13%).
¹H-NMR (CDCl₃) δ: 1.19(6H,d,J=6.6Hz), 2.89-2.98(1H,m), 3.26(6H,s), 3.72(3H,s), 7.88(1H,s).

Reference Example 13

15 Production of 2-amino-5-phenyl-4-methylthiophene-3-carboxylic acid:

2-Amino-5-phenyl-4-methylthiophene-3-carboxylic acid ethyl ester (13 mg, 50 mmol), which was obtained in Reference Example 3, was dissolved in ethanol (125
20 ml). To the solution was added 2N sodium hydroxide solution (150 ml), the mixture was refluxed under heating at 120°C for 3 hours. The reaction mixture was concentrated to dryness, the residue was partitioned between ethyl acetate (500 ml) and water. The aqueous
25 layer was extracted with ethyl acetate (200 ml), the extracts were combined, washed with an aqueous sodium chloride solution, dried with Na₂SO₄, and the solvent was distilled off to give pale brown crystals (11.45 g, 100%).

30 Reference Example 14

Production of methyl (3-oxycarbonyl-5-phenyl-4-methylthiophen-2-yl)-aminomethylene-(2-isopropylthio)acetate:

35 The compound (13.31 g, 57 mmol) obtained in Reference Example 13 and the compound (19 g, 93 mmol) obtained in Reference Example 12 were dissolved in

toluene (50 ml), and the solution was refluxed under heating at 120°C for 1.5 hours. The reaction mixture was concentrated to dryness, and the residue was purified by silica gel column chromatography to give
5 pale yellow needles (15.25 g, 77%).

m.p. 119-121°C.

mass m/z 347(M⁺)

¹H-NMR (CDCl₃) δ: 1.26(6H,d,J=6.3Hz), 2.25(3H,s), 3.15-3.24(1H,m), 3.79(3H,s), 6.40(1H,s), 7.29-7.41(5H,m),
10 7.78(1H,d,J=13.2Hz), 8.18(1H,d,J=13.8Hz).

Reference Example 15

Production of 4-hydroxy-2-phenyl-3-methyl-5-isopropylthieno[2,3-b]pyridine:

The compound (15.25 g, 43.9 mmol) obtained in
15 Reference Example 14 was added to diphenylether(150 ml) under heating (240-260°C). The mixture was stirred at the same temperature for 30 minutes. The reaction mixture was concentrated to dryness, and the residue was recrystallized from dichloromethane-n-hexane to
20 give pale yellow crystals (16 g, 103%).

Elemental Analysis for C₁₇H₁₇NOS₂·0.1H₂O:

	C(%)	H(%)	N(%)
Calcd.:	64.36	5.46	4.41
Found :	64.31	5.52	4.26

25 mass m/z 316(M⁺¹)

¹H-NMR (CDCl₃) δ: 1.30(6H,d,J=6.6Hz), 2.64(3H,s), 3.07-3.16(1H,m), 7.37-7.54(5H,m), 8.45(1H,s).

Example 1

Production of 4,7-dihydro-2-(4-methoxyphenyl)-3-methyl-5-(oxazol-5-yl)-7-(2-fluorobenzyl)-4-oxothieno[2,3-b]pyridine:
30

The compound obtained in Reference Example 10 (0.30 g, 0.73 mmol), tosylmethyisocyanide (0.144 g, 0.73 mmol), potassium carbonate (0.102 g, 0.73 mmol)
35 was added to methanol (50 ml). The mixture was refluxed under heating for two hours.

The reaction mixture was concentrated under reduced pressure to dryness. Thus obtained residues was partitioned between ethyl acetate and water. The aqueous layer was extracted with ethyl acetate, and the extracts was combined and washed with an aqueous sodium chloride solution and dried (MgSO_4), and the solvent was removed off under reduced pressure.

Purification of the residue with silica gel column chromatography gave pale yellowish solid form, and recrystalization of the solid form from dichloromethane-ethyl acetate-hexane gave colorless crystals (0.182 g, 56%).

m.p. 235-236°C

Elemental Analysis for $\text{C}_{25}\text{H}_{19}\text{N}_2\text{O}_3\text{SF}$:

	C(%)	H(%)	N(%)
Calcd.:	67.25	4.29	6.27
Found :	66.56	4.25	6.08

^1H -NMR (300MHz, CDCl_3) δ : 2.71(3H,s), 3.85(3H,s), 5.29(2H,s), 6.95(2H,d), 7.14(2H,t), 7.25(1H,td), 7.3-7.4(3H,m), 7.83(1H,s), 8.07(2H,m).

FAB-MS m/z: 447 (MH^+).

Example 2

Production of 4,7-dihydro-2-(4-methoxyphenyl)-3-bromomethyl-5-(oxazol-5-yl)-7-(2-fluorobenzyl)-4-oxothieno[2,3-b]pyridine:

A mixture of the compound produced in Example 1 (0.10 g, 0.22 mmol), N-bromosuccinimide (0.041 g, 0.24 mmol), α,α' -azobisisobutyronitrile (33 mg, 0.024 mmol), chloroform (5 ml) and carbon tetrachloride (40 ml) was refluxed under heating for one hours. After cooling resulting insolubles were filtered off from the reaction mixture. The filtrate was diluted with chloroform. The organic layer was washed with an aqueous sodium chloride solution and dried (MgSO_4), then the solvent was distilled off under reduced pressure. The residue was purified with silica gel

chromatography to give pale yellowish solid form, and then it was recrystallized from chloroform-ethyl acetate-hexane to give yellow needles (0.08 g, 69%).
m.p. 234-236°C

5 $^1\text{H-NMR}$ (300MHz, CDCl_3) δ : 3.87(3H,s), 5.08(2H,s), 5.30(2H,s), 7.01(2H,d), 7.1-7.3(3H,m), 7.40(1H,m), 7.58(2H,d), 7.84(1H,s), 8.10(2H,d).

Example 3

Production of 3-(N-benzyl-N-methylaminomethyl)-
10 4,7-dihydro-2-(4-methoxyphenyl)-5-(oxazol-5-yl)-7-(2-fluorobenzyl)-4-oxothieno[2,3-b]pyridine:

To a solution of the compound (0.07 g, 0.16 mmol) obtained in Example 2 in dimethylformamide (20 ml) are added under ice-cooling ethyldiisopropylamine (0.0243
15 g, 0.19 mmol) and N-benzylmethylamine (24.2 μl , 0.19 mmol).

After stirring for one hour at a room temperature, the reaction mixture was concentrated, and the residue was partitioned between ethyl acetate and saturated
20 sodium bicarbonate. The aqueous layer was extracted with ethyl acetate and combined with the organic layer, and dried (MgSO_4).

After removing off the solvent, the residue was purified with silica gel column chromatography to give
25 colorless powder (0.52 g, 67%). The powder was recrystallized with ethyl acetate-hexane-dichloromethane to give white crystals (0.022 g, 28%).
m.p. 144-150°C

Elemental Analysis for $\text{C}_{33}\text{H}_{28}\text{N}_3\text{O}_3\text{SF} \cdot 3\text{H}_2\text{O}$:

30

	C(%)	H(%)	N(%)
Calcd.:	63.96	5.53	6.78
Found :	63.82	4.74	6.98

$^1\text{H-NMR}$ (300MHz, CDCl_3) δ : 2.76(3H,br), 3.88(3H,s), 4.42(2H,br), 4.62(2H,br), 5.49(2H,s), 7.05(2H,d), 7.1-
35 7.5(11H,m), 7.90(1H,s), 8.01(1H,s), 8.39(1H,s).

FAB-MS m/z: 566 (MH^+).

Example 4

Production of 4,7-dihydro-2-phenyl-3-methyl-5-acetylamino-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine:

5 To a solution of O-methyl-N-methylhydroxylamine hydrochloride(25.3 g, 259.0 mmol) and diisopropylethylamine(33.5 g, 259.0 mmol) in anhydrous methylene chloride (400 ml) was added dropwise at 0°C a hexane solution (15%, 83.0 ml, 129.7 mmol) of trimethyl
10 aluminum in hexane. The mixture was allowed to warm to room temperature and stirred for further one hour. To this solution was added, with ice-cooling (0°C), a solution of the compound produced in Reference Example 9 (2) (28.5 g, 64.8 mmol) in anhydrous methylene
15 chloride (200 ml), over a period of 30 minutes. The mixture was stirred for further one hour at room temperature, to which was added chloroform (200 ml), and the mixture was washed with water. The combined organic layer was dried over sodium sulfate, which was
20 concentrated to give a solid. The solid was recrystallized from chloroform- ethyl acetate - ethyl ether to give a compound which is N-methyl-O-hydroxamic acid at 5-position.

 Thus obtained compound (27.4 g, 60.4 mmol) was
25 dissolved in anhydrous tetrahydrofuran (THF) (500 ml) under mild heating. To this solution was added dropwise, while keeping at 0°C, a solution of methyl magnesium chloride in THF (3M, 30.2 ml, 90.5 mmol), over a period of 10 minutes. The mixture was stirred
30 for further one hour. The reaction mixture was partitioned between ethyl acetate (300 ml) and water (300 ml). The aqueous layer was again extracted with ethyl acetate. The combined organic layer was dried over magnesium sulfate, which was concentrated under
35 reduced pressure. The concentrate was chromatographed on silica gel and further was recrystallized from ethyl

acetate - hexane, to give 4,7-dihydro-2-phenyl-3-methyl-5-acetyl-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine.

5 In pyridine (40 ml) is dissolved 4,7-dihydro-2-phenyl-3-methyl-5-acetyl-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine (3.66 mg, 0.89 mmol), and hydroxylamine hydrochloride (68 mg, 1.0 mmol). The mixture was stirred for 1 hour at 60°C. The reaction mixture was concentrated to dryness, and the residue
10 obtained was partitioned between chloroform (100 ml) and water. Water layer was extracted with chloroform (100 ml) and the extracts were combined and washed with an aqueous solution of sodium chloride, dried with Na₂SO₄, and the solvent was removed off under reduced
15 pressure.

Thus obtained residue was purified with silica gel chromatography to give a solid form (390 mg). Recrystallization from chloroform-ether gave white crystals (308 mg, 82%). The obtained crystals (150 mg)
20 was dissolved in pyridine (5 ml), and to the solution was added dropwise p-toluensulfonic acid chloride (74 mg, 0.39 mmol), and the mixture was stirred for one hour at room temperature. The reaction mixture was concentrated and dried, and the residue obtained was
25 partitioned between chloroform (100 ml) and water. The aqueous layer was extracted with chloroform (100 ml), and the extracts were combined, washed with an aqueous solution of sodium chloride, and dried with Na₂SO₄, and the solvent was removed off under reduced pressure.
30 The residue obtained was purified with silica gel column chromatography to give amorphous product (46 mg).

mass m/z 425(M⁺)

¹H-NMR (CDCl₃) δ: 2.20(3H,s), 2.70(3H,s), 5.23(2H,s),
35 6.99(2H,t), 7.3-7.5(6H,m), 8.53(1H,s), 9.11(1H,s).

Example 5

Production of 4,7-dihydro-2-phenyl-3-methyl-5-amino-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine:

The compound obtained in Example 4 was dissolved in ethanol, and to the solution was added an excess amount of an aqueous 2N sodium hydroxide solution. The mixture was subjected to alkali hydrolysis under heating for 24 hours to give the titled compound. mass m/z 383(M⁺)

¹H-NMR (CDCl₃) δ: 2.71(3H,s), 3.3-4.3(2H,brs), 5.14(2H,s), 6.98(2H,t), 7.17(1H,s), 7.3-7.5(6H,m).

Example 6

Production of 4,7-dihydro-2-(4-nitrophenyl)-3-methyl-5-acetoxy-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine:

4,7-dihydro-2-phenyl-3-methyl-5-acetyl-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine (500 mg, 1.1 mmol), which was obtained in the manner described in the above Example 4, was dissolved in dichloromethane (50 ml). To the solution was added m-chloroperbenzoic acid (570 mg, 1.65 mmol), and the mixture was stirred for 1.5 hours. After cooling, the reaction mixture was partitioned between dichloromethane (100 ml) and an aqueous solution of sodium bicarbonate. The aqueous layer was extracted with dichloromethane (100 ml), and the extracts were combined, washed with an aqueous sodium chloride solution, dried (Na₂SO₄) and the solvent was removed off under reduced pressure. Thus obtained residue was purified by silica gel column chromatography, recrystallized with chloroform-ether to give pale yellowish crystals (347 mg, 67%). m.p. 216-217 °C.

Example 7

Production of 4,7-dihydro-2-(4-nitrophenyl)-3-methyl-5-isopropoxy-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine:

The compound (2.16 g, 4.75 mmol) obtained in Example 6 was dissolved in tetrahydrofuran (100 ml). To the solution was added 1N sodium hydroxide (12 ml), and the mixture was stirred for one hour at room temperature. The reaction mixture was concentrated to dryness, and the residue obtained was partitioned between dichloromethane (200 ml) and water. The aqueous layer was extracted with dichloromethane (200 ml), the extracts were combined, washed with an aqueous sodium chloride solution, dried with Na₂SO₄, and the solvent was removed off under reduced pressure. The obtained residue was purified by silica gel column chromatography to give amorphous product (1.80 g).

The compound (1.41 g, 3.29 mmol) obtained in the above was dissolved in dimethylformamide (40 ml). To the solution was added isopropyl iodide (2.02 g, 16.46 mmol) and potassium carbonate (2.27 g, 16.46 mmol), and the mixture was stirred for 24 hours at 50°C. The reaction mixture was concentrated to dryness, and the residue was partitioned between chloroform (300 ml) and water. The aqueous layer was extracted with chloroform (300 ml) and the extracts were combined, washed with an aqueous sodium chloride solution, dried with Na₂SO₄, and the solvent was removed off under reduced pressure. The obtained residue was purified by silica gel column chromatography and recrystallized from chloroform-ether-n-hexane to give pale yellow crystals (550 mg, 36%).

m.p. 188-189 °C.

Mass m/z 471(M⁺)

¹H-NMR (CDCl₃) δ: 1.30(6H,d), 2.75(3H,s), 4.67(1H,m), 5.18(2H,s), 7.01(2H,t), 7.3-7.5(2H,m), 7.61(2H,d), 8.29(2H,d).

Example 8

(1) Using the compound obtained in Example 7 and by a similar manner as in Example 2, the following compound

was produced.

4,7-dihydro-2-(4-nitrophenyl)-3-bromomethyl-5-isopropoxy-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine.

5 Yellow amorphous.

¹H-NMR (CDCl₃) δ: 1.31(6H,d), 4.68(1H,m), 5.04(2H,s), 5.27(2H,s), 7.03(2H,t), 7.4-7.5(2H,m), 7.85(2H,d), 8.33(2H,d).

10 (2) The compound obtained in Example 8(1) was used and by a similar manner as in Example 3, the following compound was produced.

4,7-dihydro-2-(4-nitrophenyl)-3-(N-benzyl-N-methylaminomethyl)-5-isopropoxy-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine.

15 Yellow amorphous.

¹H-NMR (CDCl₃) δ: 1.33(6H,d), 2.23(3H,s), 3.70(2H,s), 4.23(2H,s), 4.64(1H,m), 5.22(2H,s), 7.01(2H,t), 7.1-7.5(7H,m), 8.11(2H,d), 8.23(2H,d).

20 (3) The compound obtained in Example 8(2) was used and by a similar manner as in Example 20 below mentioned, the following compound was produced.

4,7-dihydro-2-(4-aminophenyl)-3-(N-benzyl-N-methylaminomethyl)-5-isopropoxy-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine.

25 Colorless amorphous.

¹H-NMR (CDCl₃) δ: 1.30(6H,d), 2.18(3H,s), 3.70(2H,s), 3.92(2H,brs), 4.18(2H,s), 5.16(2H,s), 6.70(2H,d), 6.95(2H,t), 7.1-7.5(7H,m), 7.60(2H,d).

30 (4) The compound obtained in Example 8(3) was used and by a similar manner as in Example 21 below mentioned, the following compound was produced.

4,7-dihydro-2-(4-isobutyrylamino-phenyl)-3-(N-benzyl-N-methylaminomethyl)-5-isopropoxy-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine.

35 Yellow amorphous.

¹H-NMR (CDCl₃) δ: 1.21(6H,d), 1.35(6H,d), 2.42(3H,s),

2.95(1H,m), 3.73(2H,s), 4.25(2H,s), 4.63(1H,m),
5.35(2H,s), 6.99(2H,t), 7.2-7.5(8H,m), 7.69(1H,s),
7.95(2H,d), 9.82(1H, brs).

Example 9

5 Production of 4,7-dihydro-2-(4-
isobutyrylamino-phenyl)-3-(N-benzyl-N-
methyaminomethyl)-5-hydroxy-7-(2,6-difluorobenzyl)-4-
oxothieno[2,3-b]pyridine:

10 The compound (360 mg, 0.57 mmol) obtained in
Example 8(4) was dissolved in dichloromethane (25 ml).
To the solution a solution of boron trichloride (1.0 M)
in dichloromethane (2.29 ml) was added, and the mixture
was stirred for 1.5 hours under ice-cooling (0°C). To
the reaction mixture was added water, and the solution
15 was partitioned between chloroform (100 ml) and an
aqueous sodium bicarbonate solution. The aqueous layer
was extracted with chloroform (100 ml), the extracts
were combined, washed with an aqueous sodium chloride
solution, dried with Na₂SO₄, and the solvent was
20 removed off under reduced pressure:

 Thus obtained residue was purified by silica gel
column chromatography to give pale red amorphous (210
mg, 63%).

25 ¹H-NMR (CDCl₃) δ: 1.25(6H,d), 2.12(3H,s), 2.60(1H,m),
3.63(2H,s), 4.14(2H,s), 5.17(2H,s), 6.98(2H,t), 7.1-
7.3(5H,m), 7.3-7.5(2H,m), 7.5-7.9(5H,m).

Example 10

30 Production of 4,7-dihydro-2-(4-
isobutyrylamino-phenyl)-3-(N-benzyl-N-
methyaminomethyl)-5-isopropylsulfonyloxy-7-(2,6-
difluorobenzyl)-4-oxothieno[2,3-b]pyridine
hydrochloride:

35 The compound (50 mg) obtained in Example 9 was
dissolved in dichloromethane (5 ml). To the solution
were added dropwise isopropylsulfonyl chloride (31 mg,
0.27 mmol) and triethylamine (17 mg, 0.17 mmol) under

ice-cooling. After the addition, the mixture was stirred for one hour. The reaction mixture was concentrated to dryness, and the residue was partitioned between dichloromethane (50 ml) and water.

5 The aqueous layer was extracted with dichloromethane (50 ml), and the extracts were combined, washed with an aqueous sodium chloride solution, dried with Na_2SO_4 , and the solvent was removed off under reduced pressure. The residue was
10 purified by silica gel column chromatography to give amorphous product (30 mg, 51%).

In a similar manner as in Example 22 mentioned below, a hydrochloride of the titled compound was obtained as white crystals (13 g, 41%).

15 Hydrochloride:

m.p. 172-177°C.

mass m/z 694(M^{+1}).

^1H -NMR (CDCl_3) δ : 1.13(6H,d), 1.55(6H,dd), 2.55(3H,d),
2.67(1H,m), 4.01(1H,m), 4.2-4.5(3H,m), 4.60(1H,dd),
20 5.70(2H,s), 7.24(2H,t), 7.3-7.5(7H,m), 7.56(1H,m),
7.83(2H,d), 8.86(1H,s), 10.26(1H,s), 10.81(1H,brs).

Example 11

Production of 4,7-dihydro-2-(4-isobutyrylamino-phenyl)-3-(N-benzyl-N-methylaminomethyl)-5-isobutyryloxy-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine
25 hydrochloride:

The compound obtained in Example 9 was subjected to a similar procedure as in Example 10, using
30 isobutyryl chloride instead of isopropyl chloride, and the titled compound was obtained.

m.p. 169-172°C.

mass m/z 658(M^{+1})

^1H -NMR (CDCl_3) δ : 1.16(6H,d), 1.30(6H,dd), 2.59(3H,d),
35 2.64(1H,m), 2.90(1H,m), 4.06(1H,m), 4.3-4.6(3H,m),
5.65(2H,s), 7.2-7.5(9H,m), 7.57(1H,m), 7.85(2H,d),

8.66(1H,s), 10.23(1H,s), 11.70(1H,brs).

Example 12

Production of 4,7-dihydro-2-(4-isobutyrylamino-phenyl)-3-(N-benzyl-N-methylaminomethyl)-5-ethoxycarbonylmethoxy-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine and its hydrochloride:

The compound obtained in Example 9 was subjected to a similar procedure as in Example 7, using ethyl acetate bromide instead of isobutyryl chloride, the titled compound and its hydrochloride were obtained. Free form.

¹H-NMR (CDCl₃) δ: 1.2-1.3(9H,m), 2.20(3H,s), 2.83(1H,brs), 3.74(2H,s), 4.1-4.2(4H,m), 4.82(2H,s), 5.22(2H,s), 6.97(2H,t), 7.0-7.3(7H,m), 7.39(1H,m), 7.58(1H,brs), 7.83(2H,brs).

Hydrochloride:

m.p. 190-194°C.

mass m/z 674(M⁺)

¹H-NMR (DMSO-d₆) δ: 1.12(6H,d), 1.23(3H,t), 2.61(3H,d), 2.67(1H,m), 4.18(2H,q), 4.2-4.6(4H,m), 4.87(2H,s), 5.62(2H,s), 7.3-7.5(9H,m), 7.56(1H,m), 7.83(2H,d), 8.37(1H,s), 10.28(1H,s), 11.87(1H,brs).

Example 13

Production of 4,7-dihydro-2-(4-isobutyrylamino-phenyl)-3-(N-benzyl-N-methylaminomethyl)-5-carbamoylmethoxy-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine:

The free form (87 mg, 0.17 mmol) obtained in Example 12 was dissolved in 3 ml of ethanol, and to the solution was added 8.6M ammonium-ethanol (2 ml). The mixture was stirred for 16 hours, and the reaction mixture was concentrated to dryness. The resultant was purified by silica gel column chromatography, and recrystallized from chloroform-ether to give white crystals.

m.p. 237-238°C.

mass m/z 645(M⁺)

¹H-NMR (CDCl₃) δ: 1.28(6H,d), 2.11(3H,s), 2.56(1H,m),
3.65(2H,s), 4.14(2H,s), 4.47(2H,s), 5.21(2H,s),
5.58(1H,brs), 7.01(2H,t), 7.1-7.3(6H,m), 7.4-7.5(2H,m),
7.62(2H,d), 7.78(2H,d), 8.78(1H,brs).

Example 14

Production of 4,7-dihydro-2-phenyl-3-methyl-5-isopropylthio-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine:

To a solution of compound (6.0 g, 19 mmol) obtained in Reference Example 15 in dimethylformamide (250 ml) were added potassium carbonate (2.89 g, 21 mmol), 2,6-difluorobenzyl chloride (3.40 g, 21 mmol) and potassium iodide (0.79 g) at room temperature.

The reaction mixture was concentrated to dryness, and the residue was partitioned between chloroform (500 ml) and water. The aqueous layer was extracted with chloroform (200 ml), the extracts were combined, washed with an aqueous sodium chloride solution, dried with Na₂SO₄, and the solvent was distilled off under reduced pressure.

Thus obtained residue was purified by silica gel column chromatography to obtain colorless amorphous product (10.7 g, 48%), and recrystallized from dichloromethane-n-hexane to give pale yellow crystals. m.p. 129-131°C.

Elemental Analysis for C₂₄H₂₁NOS₂F₂•0.3H₂O:

	C(%)	H(%)	N(%)
Calcd.:	64.49 ;	4.87 ;	3.13
Found :	64.53 ;	4.79 ;	3.18

mass m/z 442(M⁺)

¹H-NMR (CDCl₃) δ: 1.24(6H,d,J=6.6Hz), 2.67(3H,s), 3.61-3.70(1H,m), 5.20(2H,s), 6.98(2H,t,J=8.04Hz), 7.33-7.43(6H,m), 7.86(1H,s).

Example 15

Production of 4,7-dihydro-2-phenyl-3-methyl-5-isopropylsulfinyl-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine:

5 The compound (2.20 g, 50 mmol) obtained in Example 14 was dissolved in dichloromethane (200 ml). To the solution was added dropwise m-chloroperbenzoic acid (0.99 g, 21 mmol) in dichloromethane (200 ml) for one hour under ice-cooling. After the addition, the mixture was stirred for 10 minutes, and the reaction
10 mixture was partitioned between chloroform (300 ml) and saturated sodium bicarbonate. The aqueous layer was extracted with chloroform (100 ml), the extracts were combined, washed with an aqueous sodium chloride solution, dried with Na₂SO₄, and the solvent was
15 distilled off under reduced pressure.

Thus obtained residue was purified by silica gel column chromatography to give colorless amorphous product (2.16 g, 85%), and recrystallized from dichloromethane-ether-n-hexane to give pale yellow
20 crystals.

m.p. 217-219°C.

Elemental Analysis for C₂₄H₂₁NO₂S₂F₂•0.2H₂O:

	C(%)	H(%)	N(%)
Calcd.:	62.51	4.68	3.04
25 Found :	62.48	4.57	3.02

Mass m/z 458(M⁺)

¹H-NMR (CDCl₃) δ: 1.04(6H,d,J=6.8Hz), 2.63(3H,s), 3.44-3.60(1H,m), 5.29-5.41(2H,Abq,J=15.3Hz), 6.94-7.48(8H,m), 7.87(1H,d,J=1.44Hz).

30 Example 16

Production of 4,7-dihydro-2-phenyl-3-methyl-5-isopropylsulfonyl-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine:

35 In Example 15, the titled compound was obtained as pale yellow crystals (0.1 g, 8%) as a by-product.
m.p. 231-233°C.

Elemental Analysis for $C_{24}H_{21}NO_2S_2F_2 \cdot 0.2H_2O$:

	C(%)	H(%)	N(%)
Calcd.:	60.87	4.47	2.96
Found :	61.16	4.33	3.07

5 Mass m/z 474 (M^{+1})

1H -NMR ($CDCl_3$) δ : 1.36(6H,d,J=6.8Hz), 2.64(3H,s), 4.07-4.16(1H,m), 5.33(2H,s), 7.00(2H,t,J=8.1Hz), 7.37-7.45(6H,m), 8.37(1H,s).

Example 17

10 Production of 4,7-dihydro-2-(4-nitrophenyl)-3-methyl-5-isopropylsulfinyl-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine:

To a solution of the compound (915 mg, 2 mmol) obtained in Example 15 in conc. sulfuric acid (12 ml) was added dropwise a sodium nitrate solution in conc. sulfuric acid (4 ml) under ice-cooling for 30 minutes. The mixture was stirred for 3 hours, and the reaction mixture was partitioned between chloroform (300 ml) and ice-water. The aqueous layer was extracted with chloroform (100 ml), the extracts were combined, washed with an aqueous sodium chloride solution, dried with Na_2SO_4 , and the solvent was distilled off. Thus obtained residue was recrystallized from dichloromethane-ether-n-hexane to give yellow crystals (1.03 g, 100%).
m.p. 212-214°C.

Elemental Analysis for $C_{24}H_{20}N_2O_4S_2F_2 \cdot 0.2H_2O$:

	C(%)	H(%)	N(%)
Calcd.:	56.95	4.06	5.53
Found :	56.91	4.03	5.47

30 Mass m/z 503 (M^{+1})

1H -NMR ($CDCl_3$) δ : 1.04(6H,d,J=6.9Hz), 1.51(3H,d,J=7.1Hz), 2.68(3H,s), 3.47-3.56(1H,m), 5.31-5.43(2H,Abq,J=15.0Hz), 7.01(2H,t,J=8.1Hz), 7.37-7.47(1H,m), 7.58-8.32(4H,Abq,J=8.7Hz), 7.90(1H,s).

Example 18

Production of 4,7-dihydro-2-(4-nitrophenyl)-3-bromomethyl-5-isopropylsulfinyl-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine:

The compound (980 mg, 2 mmol) obtained in Example 17, N-bromosuccinimide (NBS) (0.36 g, 2.04 mmol) and α,α -azobisisobutyronitrile (AIBN) (60 mg, 0.37 mmol) were suspended in carbon tetrachloride (250 ml). The mixture was refluxed under heating for 3 hours. After cooling, the reaction mixture was partitioned between chloroform (300 ml) and an aqueous sodium bicarbonate solution. The aqueous layer was extracted with chloroform (100 ml), the extracts were combined, washed with an aqueous sodium chloride solution, dried with Na_2SO_4 , and the solvent was distilled off. Thus obtained residue was recrystallized from dichloromethane-n-hexane to give yellow crystals (1.09 g, 96%).

m.p. 176-181°C.

Elemental Analysis for $\text{C}_{24}\text{H}_{19}\text{N}_2\text{O}_4\text{S}_2\text{F}_2\text{Br}\cdot 0.4\text{H}_2\text{O}$:

	C(%)	H(%)	N(%)
Calcd.:	49.58	3.39	4.76
Found :	49.09	3.36	4.79
Mass m/z	581, 583 (M^{+1})		
^1H -NMR (CDCl_3) δ :	1.05(6H,d,J=6.6Hz), 1.51(3H,d,J=7.1Hz), 3.50-3.60(1H,m), 4.88-4.99(2H,Abq,J=9.6Hz), 5.38(2H,s), 7.02(2H,t,J=8.1Hz), 7.39-7.49(1H,m), 7.81-8.38(4H,Abq,J=8.5Hz), 7.95(1H,s).		

Example 19

Production of 4,7-dihydro-2-(4-nitrophenyl)-3-(N-benzyl-N-methylaminomethyl)-5-isopropylsulfinyl-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine:

The compound (1.04 g, 1.8 mmol) obtained in Example 18 was dissolved in dimethylformamide (70 ml). To the solution was added diisopropylaminoethyl (1.15 g, 8.9 mmol) and N-methylbenzylamine (0.54 g, 4.5 mmol) at room temperature, and the mixture was further

stirred for one hour. The reaction mixture was concentrated to dryness, and the residue was partitioned between ethyl acetate (300 ml) and water. The aqueous layer was extracted with ethyl acetate (100 ml), the extracts were combined, washed with an aqueous sodium chloride solution, dried with Na_2SO_4 , and the solvent was distilled off. Thus obtained residue was purified by silica gel column chromatography to give a solid form (1.09 g), and recrystallization from dichloromethane-ether-n-hexane gave pale yellow crystals (1.03 g, 93%).

m.p. 98-103°C.

Elemental Analysis for $\text{C}_{32}\text{H}_{29}\text{N}_3\text{O}_4\text{S}_2\text{F}_2 \cdot 0.8\text{H}_2\text{O}$:

	C(%)	H(%)	N(%)
15 Calcd.:	60.42	4.85	6.61
Found :	60.40	4.70	6.71
Mass m/z 622.2 (M^{+1})			
$^1\text{H-NMR}$ (CDCl_3) δ : 1.04(6H,d,J=6.8Hz),			
1.52(3H,d,J=7.1Hz), 2.19(3H,s), 3.47-3.56(1H,m),			
20	3.63(2H,s), 4.01-4.25(2H,Abq,J=11.9Hz), 5.32-		
5.43(2H,Abq,J=15.3Hz), 7.02(2H,t,J=8.1Hz), 7.13-			
7.48(6H,m), 7.90(1H,s), 8.06-8.28(4H,Abq,J=8.8Hz).			

Example 20

Production of 4,7-dihydro-2-(4-aminophenyl)-3-(N-benzyl-N-methylaminomethyl)-5-isopropylsulfinyl-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine:

The compound (0.54 g, 0.87 mmol) obtained in Example 19 and iron powder (0.26 g, 4.3 mmol) were added to methanol (10 ml) and to the mixture conc. hydrogen chloride (5 ml) was added dropwise for one hour. The mixture was stirred for 5 hours under ice-cooling. To the reaction mixture saturated sodium bicarbonate (30 ml) was added carefully. After adding chloroform (50 ml) and Celite, the mixture was subjected to filtration.

The aqueous layer was extracted with chloroform

(100 ml), the extracts were combined, washed with an aqueous sodium chloride solution, dried with Na_2SO_4 , and the solvent was distilled off. Thus obtained residue was recrystallized from dichloromethane-n-hexane to give pale yellow crystals (0.46 g, 89%).
m.p. 105-115°C.

Elemental Analysis for $\text{C}_{32}\text{H}_{31}\text{N}_3\text{O}_2\text{S}_2\text{F}_2 \cdot 0.5\text{H}_2\text{O}$:

	C(%)	H(%)	N(%)
Calcd.:	63.98	5.37	6.99

Found :	64.09	5.50	6.82
---------	-------	------	------

Mass m/z 592(M^{+1})

^1H -NMR (CDCl_3) δ : 1.03(6H,d,J=6.8Hz),

1.50(3H,d,J=7.1Hz), 2.11(3H,s), 3.48-3.58(1H,m),

3.61(2H,s), 3.87(2H,brs), 3.96-4.18(2H,Abq,J=12Hz),

5.28-5.39(2H,Abq,J=15.3Hz), 6.71-7.63(4H,Abq,J=8.7Hz),

6.98(2H,t,J=8.1Hz), 7.12-7.44(6H,m), 7.85(1H,s).

Example 21

Production of 4,7-dihydro-2-(4-isobutyrylamino-phenyl)-3-(N-benzyl-N-methylaminomethyl)-5-isopropylsufinyl-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine:

To a solution of the compound (0.41 mg, 0.69 mmol) obtained in Example 20 in dichloromethane (20 ml) were added triethylamine (0.70 g, 7.0 mmol) and isobutyryl chloride (0.36 g, 3.5 mmol) under ice-cooling. The mixture was stirred for one hour under ice-cooling. To the reaction mixture was added a saturated aqueous sodium bicarbonate solution (30 ml), and the mixture was extracted with chloroform (20 ml). The extracted aqueous layer was further extracted with chloroform (20 ml), the extracts were combined, washed with an aqueous sodium chloride solution, dried with Na_2SO_4 , and the solvent was distilled off. Thus obtained residue was purified by silica gel column chromatography to give amorphous product (0.35 g, 77%).

^1H -NMR (CDCl_3) δ : 1.04(6H,d,J=6.8Hz),

1.27(3H,d,J=6.8Hz), 1.51(3H,d,J=7.1Hz), 2.16(3H,s),
2.07-2.67(1H,m), 3.48-3.60(1H,m), 3.68(2H,s), 4.02-
4.22(2H,Abq,J=12Hz), 5.31-5.42(2H,Abq,J=15.0Hz),
6.99(2H,t,J=8.1Hz), 7.14-7.45(6H,m), 7.68-7.75(4H,m),
5 7.86(1H,s), 7.93(1H,s).

Example 22

Production of 4,7-dihydro-2-(4-isobutyrylamino-phenyl)-3-(N-benzyl-N-methylaminomethyl)-5-isopropylsulfinyl-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine hydrochloride:

The compound (0.35 g, 0.53 mmol) obtained in Example 21 was dissolved in dichloromethane (5 ml). To the solution was added 1M hydrogen chloride in ether (1.06 ml, 1.06 mmol) under ice-cooling. The mixture was stirred for 30 minutes, the solvent was distilled off under reduced pressure. Thus obtained residue was recrystallized from dichloromethane-n-hexane to give pale yellow crystals (0.30 g, 77%).
m.p. 185-187°C.

Elemental Analysis for $C_{36}H_{37}N_3O_4S_2F_2 \cdot HCl \cdot 2H_2O$:

	C(%)	H(%)	N(%)
Calcd.:	58.88	5.76	5.72
Found :	59.08	5.74	5.78

Mass m/z 662(M^{+1})
 1H -NMR ($CDCl_3$) δ : 0.98-1.46(6H,m), 1.13(6H,d,J=6.3Hz), 2.64-2.73(1H,m), 2.67(3H,d,J=4.6Hz), 3.33-3.43(1H,m), 4.20-4.60(4H,m), 5.69-5.96(2H,m), 7.21-7.87(12H,m), 8.37(1H,s), 10.29(1H,s), 10.78(0.5H,s), 10.88(0.5H,s).


Example 23

The compound obtained in Example 16 is subjected to the reactions similar to those described in Examples 17, 18, 19, 20, 21 or 22, or the compound obtained in Example 22 is subjected to the reactions similar to those described in Examples 15 or 16, the following compound is produced:

4,7-dihydro-2-(4-isobutyrylamino-phenyl)-3-(N-benzyl-N-methylaminomethyl)-5-isopropylsulfonyl-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine.


The compounds shown in the above Examples are listed in the following tables 1 to 3.

Table 1




Example No.	R ¹ (3-position)
1	methyl
2	bromomethyl
3	N-benzyl-N-methylaminomethyl

Table 2



Example No.	R ¹ (3-position)	R ² (2-position)	R ⁴ (5-position)
4	methyl	phenyl	acetylamino
5	methyl	phenyl	amino
6	methyl	4-nitrophenyl	acetoxy
7	methyl	4-nitrophenyl	isopropoxy
8(1)	bromomethyl	4-nitrophenyl	isopropoxy
8(2)	N-benzyl-N-methylaminomethyl	4-nitrophenyl	isopropoxy
8(3)	N-benzyl-N-methylaminomethyl	4-aminophenyl	isopropoxy
8(4)	N-benzyl-N-methylaminomethyl	4-isobutyryl-aminophenyl	isopropoxy
9	N-benzyl-N-methylaminomethyl	4-isobutyryl-aminophenyl	hydroxy
10	N-benzyl-N-methylaminomethyl	4-isobutyryl-aminophenyl	isopropyl-sulfonyloxy
11	N-benzyl-N-methylaminomethyl	4-isobutyryl-aminophenyl	isobutyryloxy
12	N-benzyl-N-methylaminomethyl	4-isobutyryl-aminophenyl	ethoxycarbonyl-methoxy
13	N-benzyl-N-methylaminomethyl	4-isobutyryl-aminophenyl	carbamoyl-methoxy
14	methyl	phenyl	isopropylthio
15	methyl	phenyl	isopropyl-sulfinyl

Table 3



10

15

20

Example No.	R ¹	R ²	R ⁴
16	methyl	phenyl	isopropylsulfonyl
17	methyl	4-nitrophenyl	isopropylsulfinyl
18	bromomethyl	4-nitrophenyl	isopropylsulfinyl
19	N-benzyl-N-methylaminomethyl	4-nitrophenyl	isopropylsulfinyl
20	N-benzyl-N-methylaminomethyl	4-aminophenyl	isopropylsulfinyl
21	N-benzyl-N-methylaminomethyl	4-isobutyryl-aminophenyl	isopropylsulfinyl
22	N-benzyl-N-methylaminomethyl	4-isobutyryl-aminophenyl	isopropylsulfinyl
23	N-benzyl-N-methylaminomethyl	4-isobutyryl-aminophenyl	isopropylsulfonyl

Example 24

Using the compound produced in Example 3, lactose (165 mg), cornstarch (25 mg), polyvinyl alcohol (4 mg) and magnesium stearate (1 mg), tablets are prepared by a conventional method.

Example 25

The compound produced in Example 3 is dissolved in distilled water for injection to make the whole volume 100 ml. This solution is subjected to sterilized filtration through 0.22 μ m membrane filter (manufactured by Sumitomo Electric Industries, Ltd. or Zartolius Inc.), 2 ml each of which is divided into sterilized vials, followed by lyophilization to prepare a lyophilized injectable composition of 100 mg/vial.

Example 26

The compound produced in Example, lactose (165 mg), cornstarch (25 mg), polyvinyl alcohol (4 mg) and magnesium stearate (1 mg), tablets are prepared by a conventional method.

Example 27

The compound produced in Example 8(4) is dissolved in distilled water for injection to make the whole volume 100 ml. This solution is subjected to sterilized filtration through 0.22 μ m membrane filter (manufactured by Sumitomo Electric Industries, Ltd, or Zartolius Inc.), 2 ml each of which is divided into sterilized vials, followed by lyophilization to prepare a lyophilized injectable composition of 100 mg/vial.

Example 28

The compound produced in Example 10, lactose (165 mg), cornstarch (25 mg), polyvinyl alcohol (4 mg) and magnesium stearate (1 mg), tablets are prepared by a conventional method.

Example 29

The compound produced in Example 10 is dissolved in distilled water for injection to make the whole

volume 100 ml. This solution is subjected to sterilized filtration through 0.22 μ m membrane filter (manufactured by Sumitomo Electric Industries, Ltd. or Zartolius Inc.), 2 ml each of which is divided into
 5 sterilized vials, followed by lyophilization to prepare a lyophilized injectable composition of 100 mg/vial.

Example 30

	(1) Compound produced in Example 3	5 g
	(2) Lactose.crystalline cellulose (granules)	330 g
10	(3) D-mannitol	29 g
	(4) Low-substituted hydroxypropyl cellulose	20 g
	(5) Talc	25 g
	(6) Hydroxypropyl cellulose	50 g
	(7) Aspartame	3 g
15	(8) Dipotassium glycyrrhetinate	3 g
	(9) Hydroxypropylmethyl cellulose 2910	30 g
	(10) Titanium oxide	3.5 g
	(11) Yellow iron sesquioxide	0.5 g
	(12) Light silicic acid anhydride	1 g
20	In refined water are suspended or dissolved (1), (3), (4), (5), (7) and (8). The nuclear granule of (2) is coated with the suspension or solution to prepare raw fine granules, which are coated with (9)-(11) to prepare coated fine granules, which are mixed with	
25	(12), to give 500 g of fine granules containing 1% of the compound produced in Example 3. 500 mg each of thus-prepared fine granules is packed.	

Test Example 1

30 (1) Preparation of ^{125}I -leuprorelin
 Ten μ l of a $3 \times 10^{-4}\text{M}$ aqueous solution of leuprorelin and 10 μ l of 0.01 mg/ml lactoperoxidase in 0.1M HEPES buffer (pH 7.4) were taken into a tube, to which was added 10 μ l [37MBq in 0.1M HEPES buffer (pH
 35 7.4)] of an Na^{125}I solution. The mixture was stirred, to which was added 10 μ l of 0.001% H_2O_2 , then reaction

- was allowed to proceed for 20 minutes at room temperature. To the reaction mixture was added 700 μ l of a 0.05% TFA solution to stop the reaction. The product was purified by means of reversed phase HPLC.
- 5 Conditions of HPLC are as follows. 125 I-leuprorelin was eluted at a retention time of 26 to 27 minutes.
- Column : TSK gel ODS-80TMCTR (4.6 mm x 10 cm)
- Eluent : Solvent A (0.05% TFA)
- Solvent B (40%CH₃CN-0.05% TFA)
- 10 0 minute (100% Solvent A) - 3 minutes (100% Solvent A) - 7 minutes (50% Solvent A + 50% Solvent B) - 40 minutes (100% Solvent B)
- Elution temp.: room temperature
- Flow rate : 1 ml/min.
- 15 (2) Preparation of membrane fraction of CHO (Chinese Hamster Ovary) cells containing human GnRH receptors
- CHO cells (10^9) expressing human GnRH receptors were suspended in a phosphate-buffered saline supplemented with 5mM EDTA (PBS-EDTA). The suspension
- 20 was subjected to centrifugal separation for 5 minutes at 100xg. To the pellet of cells was added 10 ml of a homogenate buffer for cells (10 mM NaHCO₃, 5 mM EDTA (ethylenediamine tetracetate), pH 7.5), which was homogenated by using a Polytron homogenizer.
- 25 Centrifugal separation was conducted for 15 minutes at 400xg. The supernatant was taken into an ultracentrifugal tube, which was subjected to centrifuge for one hour at 100,000xg to give precipitate of the membrane fraction. The precipitate
- 30 was suspended in 2 ml of the assay buffer (25mM Tris-HCl, 1mM EDTA, 0.1% BSA (bovine serum albumin), 0.25 mM PMSF, 1 μ g/ml pepstatin, 20 μ g/ml leupeptin, 100 μ g/ml phosphoramidon, 0.03% sodium azide, pH 7.5), which was centrifuged for one hour at 100,000xg. The membrane
- 35 fraction recovered as precipitate was again suspended in 20 ml of the assay buffer, which was distributed to

vials and stored at -80°C until used.

(3) Determination of inhibitory rate of ^{125}I -leuprorelin binding

Membrane fraction of CHO cells expressing human GnRH receptors prepared in the above (2) as diluted with an assay buffer to $200\text{ }\mu\text{g/ml}$ and $188\text{ }\mu\text{l}$ each was distributed into tubes.

$2\text{ }\mu\text{l}$ of 2mM of the compound dissolved in 60% DMSO and $10\text{ }\mu\text{l}$ of 38 nM ^{125}I -leuprorelin were added simultaneously to the CHO cell membrane fraction expressing human GnRH receptors. For determining the amount of maximum binding, a solution for reaction supplemented with $2\text{ }\mu\text{l}$ of 60% DMSO and $10\text{ }\mu\text{l}$ of 38 nM ^{125}I -leuprorelin was prepared. And, for determining the amount of non-specific binding, a solution for reaction supplemented with $2\text{ }\mu\text{l}$ of $100\text{ }\mu\text{M}$ leuprorelin dissolved in 60% DMSO and $10\text{ }\mu\text{l}$ of 38 nM ^{125}I -leuprorelin were also prepared simultaneously.

The reaction was allowed to proceed at 25°C for 60 minutes. The reaction mixtures were respectively subjected to filtration under sucking with Whatman glass filter (GF-F) processed with polyethylenimine. After completing the filtration, radioactivity of the ^{125}I -leuprorelin remaining on the filter paper was measured with a γ -counter.

By calculation of

$$\text{PMB} = (\text{TB} - \text{SB}) / (\text{TB} - \text{NSB}) \times 100$$

(TB: maximum binding radioactivity, SB: radioactivity obtained when a compound was added, NSB: non-specific binding ratio activity, the binding inhibitory rate (PMB) (%) of each test compound was determined. Besides, the inhibitory rates were determined by changing the concentrations of test compounds, and the concentration of a test compound inhibiting the (TB-NSB) by 50% , i.e. the concentration of $\text{PMB}=50\%$, (IC_{50} value) was calculated by way of Hill plot.

The compounds obtained in Examples 8(4), 10, 11 or 12 were subjected to the above measurement methods, and obtained IC₅₀ values shown in the following Table 4.

Table 4

5 ¹²⁵I-leuprorelin binding inhibitory rate

Test compound	IC ₅₀ value (nM)
	human GnRH receptor
Compound of Example 8(4)	1
Compound of Example 10	0.3
10 Compound of Example 11	2
Compound of Example 12	3

Industrial Applicability

15 The gonadotropin-releasing hormone antagonistic agent of the present invention is stably absorbed through oral administration and shows GnRH antagonistic activity over a long time. Therefore, the present compound can be used as a prophylactic or therapeutic agent for the prevention or treatment of several hormone dependent diseases, for example, a sex hormone dependent cancer, e.g. prostatic cancer (pituitary adenoma), cancer of the uterine cervix, breast cancer, prostatic hypertrophy, myoma of the uterus, endometriosis, precocious puberty, amenorrhea syndrome, polycystic ovary syndrome and acne vulgaris, or as a fertility controlling agent, e.g. a contraceptive agent, infertility treating agent, a menstruation controlling agent. Further, in the field of animal husbandry, the gonadotropin-releasing hormone antagonistic agent of the present invention is effective as an agent of controlling oestrus in animals, improving the quality of edible meat, growth regulation of animals, and also a spawning-accelerating agent in the field of fisheries.

20

25


30

35


CLAIMS

What we claim is:

1. A compound of the formula:



wherein each of R^1 and R^2 are hydrogen or a group bonded through a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom, R^3 is an optionally substituted homo-or hetero-cyclic group, R^4 is an optionally substituted heterocyclic group or a group bonded through a hetero atom, R^5 is hydrogen or a group bonded through a carbon atom, n is an integer of 0 to 3, with the proviso that when R^4 is tetrazolyl or a group bonded through a hetero atom and n is 1, R^3 is not a group of the formula:



wherein R^7 is an optionally substituted 5-7 membered heterocyclic residue, having as a group capable of constituting the ring, carbonyl group, thiocarbonyl group, an optionally oxidized sulfur atom or a group convertible into them, D is a direct bond or a spacer having an atomic length of two or less between the ring B and the ring A, and A and B are independently an optionally substituted aromatic hydrocarbon residue optionally containing a hetero-atom or an optionally substituted heterocyclic residue, or a salt thereof.

2. A compound according to Claim 1, wherein R^1 is a group bonded through a carbon atom or a nitrogen atom.
3. A compound according to Claim 1, wherein R^1 is an optionally substituted C_{1-20} hydrocarbon residue.
4. A compound according to Claim 1, wherein R^1 is an optionally substituted C_{1-6} alkyl group.
5. A compound according to Claim 3, wherein C_{1-20} hydrocarbon residue of R^1 is optionally substituted with (1) halogen, (2) nitro, (3) cyano, (4) an optionally substituted amino, (5) an optionally substituted hydroxyl group, (6) a group of the formula: $-S(O)_t-R^6$, wherein t denotes an integer of 0 to 2, and R^6 is a hydrogen atom or an optionally substituted hydrocarbon residue.
6. A compound according to Claim 1, wherein R^2 is an optionally substituted C_{1-20} hydrocarbon residue.
7. A compound according to Claim 1, wherein R^2 is an optionally substituted C_{6-14} aryl group.
8. A compound according to Claim 1, wherein C_{1-20} hydrocarbon residue of R^2 is optionally substituted with (1) an optionally substituted amino group, (2) an optionally substituted hydroxyl group, (3) an optionally substituted carbamoyl group, (4) an optionally substituted carboxyl group, (5) an optionally substituted alkenyl group, (6) acyl or (7) nitro.
9. A compound according to Claim 1, wherein R^3 is an optionally substituted homo-cyclic group.

10. A compound according to Claim 9, wherein R^3 is an optionally substituted C_{6-14} aryl group.

11. A compound according to Claim 9, wherein homo-cyclic group of R^3 is optionally substituted with (1) halogen, (2) nitro, (3) an optionally substituted hydroxyl group, (4) a group of the formula: $-S(O)_t-R^6$, wherein t denotes an integer of 0 to 2, and R^6 is a hydrogen atom or an optionally substituted hydrocarbon residue.

12. A compound according to Claim 1, wherein heterocyclic group of R^4 is 5- to 8-membered heterocyclic group.

13. A compound according to Claim 1, wherein heterocyclic group of R^4 is 5- to 8-membered heterocyclic group having at least one nitrogen atom in a ring.

14. A compound according to Claim 1, wherein the group bonded through hetero atom of R^4 is an optionally substituted amino group, an optionally substituted hydroxyl group or an optionally substituted mercapto group.

15. A compound according to Claim 1, wherein the substituent in the optionally substituted heterocyclic group of R^4 is (1) halogen, (2) nitro, (3) an optionally substituted hydroxyl group, (4) a group of the formula: $-S(O)_t-R^6$, wherein t denotes an integer of 0 to 2, and R^6 is a hydrogen atom or an optionally substituted hydrocarbon residue, (5) an optionally substituted amino, or (6) a C_{1-10} hydrocarbon residue.

16. A compound according to Claim 14, wherein the substituent in the optionally substituted amino group, the optionally substituted hydroxyl group or the optionally substituted mercapto group is (1) a C₁₋₁₀ hydrocarbon residue which may optionally be substituted by C₁₋₆ alkoxy-carbonyl or carbamoyl, (2) a C₁₋₁₀ acyl group, or (3) a group of the formula: -S(O)_t-R⁶, wherein t denotes an integer of 0 to 2, and R⁶ is a hydrogen atom or an optionally substituted hydrocarbon residue.

17. A compound according to Claim 1, wherein R⁵ is a hydrogen atom or an optionally substituted C₁₋₂₀ hydrocarbon residue.

18. A compound according to Claim 17, wherein hydrocarbon residue in the optionally substituted C₁₋₂₀ hydrocarbon residue is C₁₋₁₀ alkyl group.

19. A compound according to Claim 1, wherein R¹ is an alkyl group which may optionally be substituted with halogen or N-C₇₋₁₃ aralkyl-N-C₁₋₆ alkylamino, R² is a C₆₋₁₄ aryl group which may optionally be substituted with a group selected from the group consisting of (i) nitro, (ii) C₁₋₆ alkoxy and (iii) amino which may optionally be substituted with C₁₋₆ alkanoyl, R³ is a mono- or di-halogeno C₆₋₁₄ aryl group, R⁴ is (1) a 5- or 6- membered heterocyclic group which has at least one nitrogen atom and one oxygen atom and which is bonded through a carbon atom, (2) a hydroxyl group which may optionally be substituted with a group selected from the group consisting of (i) C₁₋₆ alkyl which may optionally be substituted with C₁₋₆ alkoxycarbonyl or carbamoyl, (ii) C₁₋₆ alkanoyl and (iii) C₁₋₆ alkylsulfonyl, (3) a group of the formula: -S(O)_t-R^{6'}, wherein t is an integer of 0


to 2 and $R^{6'}$ is C_{1-6} alkyl, or (4) an amino group which may optionally be substituted with C_{1-6} alkanoyl, R^5 is a hydrogen atom and n is 1.

20. 4,7-dihydro-2-(4-methoxyphenyl)-3-(N-benzyl-N-methylaminomethyl)-5-(oxazol-5-yl)-7-(2-fluorobenzyl)-4-oxothieno[2,3-b]pyridine or its salt.


21. 4,7-dihydro-2-(4-isobutyrylamino-phenyl)-3-(N-benzyl-N-methylaminomethyl)-5-(isopropoxy)-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine or its salt.

22. 3-(N-benzyl-N-methylaminomethyl)-4,7-dihydro-2-(4-isobutyrylamino-phenyl)-5-(isopropylsulfonyloxy)-7-(2,6-difluorobenzyl)-4-oxothieno[2,3-b]pyridine or its salt.

23. A method for producing a compound of the formula:




wherein $R^{1'}$ is a group bonded through a nitrogen atom, R^2 , R^3 , R^4 and R^5 have the same meaning as defined in Claim 1, n is an integer of 0 to 3, m is an integer of 0 to 6, or a salt thereof, which comprises reacting a compound of the formula:



wherein X is a leaving group and the other group have the same meaning as defined above, with a compound of

the formula:



wherein $R^{1'}$ has the same meaning as defined above.

24. A pharmaceutical composition, which comprises a compound as defined in Claim 1 and a carrier, excipient or diluent thereof.

25. A pharmaceutical composition according to Claim 24, which is for antagonizing gonadotropin-releasing hormone activity.

26. A pharmaceutical composition according to Claim 25, which is a composition for treating or preventing a sex hormone dependent disease.

27. A method for treating a mammal suffering from a gonadotropin-releasing hormone derived disorder, which comprises administering an effective amount of a compound as defined in Claim 1 to the mammal.

28. Use of a compound as defined in Claim 1 for producing a pharmaceutical composition for antagonizing gonadotropin-releasing hormone activity in a mammal suffering from a sex hormone dependent disease.

INTERNATIONAL SEARCH REPORT

Inte onal Application No
PCT/JP 96/03018

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D495/04 A61K31/435 //(C07D495/04,333:00,221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 171 835 A (JANAKY TAMAS ET AL) 15 December 1992 cited in the application see abstract ---	1-28
A	EP 0 520 423 A (TAKEDA CHEMICAL INDUSTRIES LTD) 30 December 1992 cited in the application see claim 1 ---	1
P,X	WO 95 28405 A (TAKEDA CHEMICAL INDUSTRIES LTD ;FURUYA SHUICHI (JP); CHOH NOBUO (J) 26 October 1995 see claims -----	1-28



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- * "A" document defining the general state of the art which is not considered to be of particular relevance
- * "E" earlier document but published on or after the international filing date
- * "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- * "O" document referring to an oral disclosure, use, exhibition or other means
- * "P" document published prior to the international filing date but later than the priority date claimed

- * "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- * "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- * "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * "&" document member of the same patent family

Date of the actual completion of the international search

12 February 1997

Date of mailing of the international search report

20.02.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

De Jong, B

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP 96/03018

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 27 is directed to a method of treatment of (diagnostic method practised on) the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 96/03018

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US-A-5171835	15-12-92	CA-A-	2079461	31-07-92
		EP-A-	0522152	13-01-93
		WO-A-	9213883	20-08-92
		EP-A-	0364819	25-04-90
		JP-A-	2157293	18-06-90
		US-A-	5258492	02-11-93

EP-A-0520423	30-12-92	AU-B-	646343	17-02-94
		AU-A-	1859892	07-01-93
		CA-A-	2072541	28-12-92
		CN-A-	1067890	13-01-93
		HU-A-	71218	28-11-95
		HU-B-	211162	30-10-95
		JP-A-	5271228	19-10-93
		NZ-A-	243304	27-01-95
		US-A-	5354766	11-10-94
		US-A-	5583141	10-12-96
		US-A-	5243054	07-09-93
		ZA-A-	9204666	24-12-93

WO-A-9528405	26-10-95	AU-A-	2223995	10-11-95
		BR-A-	9501736	14-11-95
		CA-A-	2186124	26-10-95
		EP-A-	0756599	05-02-97
		JP-A-	8295693	12-11-96
		NO-A-	964434	18-10-96
		AU-A-	4632796	27-08-96
		WO-A-	9624597	15-08-96
